Page last updated: 2024-08-25

zoledronic acid and Kahler Disease

zoledronic acid has been researched along with Kahler Disease in 272 studies

Research

Studies (272)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (1.47)18.2507
2000's118 (43.38)29.6817
2010's130 (47.79)24.3611
2020's20 (7.35)2.80

Authors

AuthorsStudies
Berghuis, AM; De Schutter, JW; Huang, XF; Lin, YS; Park, J; Sebag, M; Tsantrizos, YS1
Berghuis, AM; Gómez Palou, M; Huang, XF; Lacbay, CM; Park, J; Sebag, M; Ta, V; Tsantrizos, YS; Vincent, F; Waller, DD1
Andoh, K; Burdalski, C; Burton, B; Gilmore, S; Goldenhorn, M; Porter, T; Proctor, C; Sproat, MR1
Berns, JS; Geara, AS; Shulman, R1
Fasciolo, A; Fusco, V; Gambino, A; Palmeri, S; Rossi, M1
Chatziravdeli, V; Doxani, C; Katsaras, D; Katsaras, GN; Stefanidis, I; Zintzaras, E1
Avonto, I; Castella, B; D'Agostino, M; Giannotta, C; Grasso, M; Grimaldi, D; Kopecka, J; Larocca, A; Massaia, M; Riganti, C; Tripoli, E1
Abe, M; Harada, T; Hiasa, M; Miki, H; Nakamura, S; Teramachi, J1
Hong, BM; Hong, WW; Kim, IH; Mupparapu, M; Oak, S1
Baek, YH; Hong, S; Jeon, HL; Oh, IS; Park, J; Shin, JY; Yang, H1
Karpiłowska, A; Podgórska, J; Popow, M; Radziszewski, M; Ziółkowska, A1
Álvarez-Yagüe, E; Junquera, L; Junquera, S; Rúa, L; Ugalde, R1
Caruso, SR; Covas, DT; de Macedo, LD; De Santis, GC; Fernandes, TR; Ferrari, TC; Innocentini, LMAR; Orellana, MD; Ricz, HMA1
Ehresman, J; Khan, M; Luna, LP; Sankaran, N; Sciubba, DM1
Chang, CS; Chng, WJ; Gao, S; Glennane, A; Gordon, SW; Huang, SY; Min, CK; Shimizu, K; Wang, Y; Wong, RS; Yoon, SS1
Chen, C; Cui, Y; Li, M; Li, R; Ma, L; Yang, T; Zhou, S; Zhou, Y1
Ntanasis-Stathopoulos, I; Terpos, E1
Canon, J; Croucher, P; Garcia-Sanz, R; Glennane, A; Leleu, X; Pasteiner, W; Pawlyn, C; Raje, N; Terpos, E; Wang, Y1
Billias, C; Langer, M; Schorr, R; Ursu, S1
Buda, G; Carulli, G; Dalla Palma, B; Fazzi, R; Galimberti, S; Giuliani, N; Morganti, R; Notarfranchi, L; Petrini, I1
Cui, X; Jiang, L; Ma, H; Tang, X1
Kanri, Y; Kobayashi, E; Minami, Y; Ogawa, R; Ogura, I; Okada, Y; Ono, J; Tanaka, A1
Abi-Hanna, D; Baldock, PA; Bassett, JHD; Cheng, TL; Croucher, PI; Fairfield, H; Falank, C; Ghobrial, IM; Hose, D; Kneissel, M; Kramer, I; Le, LMT; Little, DG; McDonald, MM; Mohanty, ST; Morse, A; Oyajobi, BO; Pettitt, JA; Phan, TG; Reagan, MR; Seckinger, A; Simic, MK; Terry, RL; Vanderkerken, K; Williams, GR; Youlten, SE1
Bagratuni, T; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kastritis, E; Melakopoulos, I; Melea, P; Migkou, M; Roussou, M; Terpos, E1
Davies, M; Kanatas, A; Power, A1
Raje, NS; Yee, AJ1
Djulbegovic, B; Kumar, A; Mhaskar, R; Miladinovic, B1
Amler, E; Amodio, N; Caraglia, M; Di Martino, MT; Grimaldi, A; Misso, G; Russo, M; Tagliaferri, P; Tassone, P; Zappavigna, S; Zarone, MR1
Cheng, P; Durie, B; García-Sanz, R; Krejčí, M; Laribi, K; Legieć, W; Raje, N; Roodman, GD; Shimizu, K; Terpos, E; Warner, D; Willenbacher, W; Zhu, L1
Dimopoulos, MA; Kastritis, E1
García-Sanz, R; Hechmati, G; Intorcia, M; Kennedy, L; Raje, N; Roodman, GD; Sabatelli, L; Shimizu, K; Terpos, E; Willenbacher, W1
Allegra, A; Allegra, AG; Avenoso, A; Campo, S; D'Ascola, A; Innao, V; Mania, M; Musolino, C; Oteri, G1
Bell, SE; Cairns, DA; Child, JA; Cook, G; Davies, FE; Drayson, MT; Gregory, WM; Jackson, GH; Morgan, GJ; Owen, RG; Royle, KL1
Kalin-Hajdu, E; Martin, TG; Narayan, R; Tan, M; Wong, SW1
Almaden, WF; Chen, Y; Gong, Y; Kashtwari, D; Katz, J; Moreb, J; Wazzan, T1
Dimopoulos, MA; Gavriatopoulou, M; Kanellias, N; Terpos, E1
Chantry, AD; Down, JM; Evans, H; Green, AC; Lath, D; Lawson, MA; Paton-Hough, J; Snowden, JA; Tazzyman, S1
Djulbegovic, B; Mhaskar, R1
Bolzoni, M; Ferretti, M; Giuliani, N; Palumbo, C; Toscani, D1
Accordino, MK; Bhutani, D; Chen, Y; Hershman, DL; Hillyer, GC; Leng, S; Lentzsch, S; Lim, E; Neugut, AI; Tsai, WY; Wright, JD1
Bhowmik, D; Campioni, M; Christodoulopoulou, A; Jamotte, A; Kennedy, L; Terpos, E; Willenbacher, W1
Dimopoulos, MA; Kleber, M; Ntanasis-Stathopoulos, I; Terpos, E1
Delaissé, JM; Hansen, CT; Jakobsen, EH; Jørgensen, HB; Plesner, T; Søe, K1
Cavo, M; Dimopoulos, MA; Drake, MT; Durie, BG; García-Sanz, R; Jurczyszyn, A; Leleu, X; Lentzsch, S; Merlini, G; Morgan, G; Munshi, N; Raje, N; Rajkumar, SV; Reiman, T; Roodman, GD; Sezer, O; Shimizu, K; Spencer, A; Terpos, E; Turesson, I1
Blanquer, M; Gonzálvez-García, M; Moraleda, JM; Oñate-Sánchez, R; Rodríguez-González, MA; Rodríguez-Lozano, FJ; Segarra-Fenoll, D; Villanueva, V1
Cho, SH; Chul-Hyun, L; Go, BS; Kim, SW; Kim, WC1
Delabaye, I; Delforge, M; Doyen, C; Duck, L; Van den Wyngaert, T; Wildiers, H; Wouters, C; Wouters, K1
Boccadoro, M; Brioli, A; Child, JA; Cook, G; Davies, FE; Drayson, MT; Gregory, WM; Jackson, GH; Larocca, A; Morgan, GJ; Owen, RG; Palumbo, A; Russell, N; Szubert, A; Wu, P1
Soydan, SS; Uckan, S1
Arra, C; Bruzzese, F; Budillon, A; Caraglia, M; Chianese, MI; Ciardiello, C; Di Gennaro, E; Franco, R; Leone, A; Luciano, A; Milone, MR; Pucci, B; Rocco, M; Santini, D1
Body, JJ3
Costa, L; Dansey, R; Feng, A; Henry, D; Hirsh, V; Hungria, V; Jun, S; Scagliotti, G; Smith, G; Vadhan-Raj, S; von Moos, R; Woll, PJ; Yeh, H1
Delaissé, JM; Hansen, CT; Jakobsen, EH; Plesner, T; Søe, K1
Brown, J; Fullarton, JR; Palmieri, C1
Bokhari, SW; Jones, FM1
Alegre, A; Bailén, A; Giraldo, P; Gironella, M1
Berk, V; Cetin, M; Elmali, F; Enhos, S; Eser, B; Inanc, M; Karaca, H; Kaynar, L; Ozkan, M; Pala, C; Sıvgın, S1
Ashcroft, AJ; Bell, SE; Boyd, KD; Byrne, J; Child, JA; Cook, G; Davies, FE; Drayson, MT; Feyler, S; Gregory, WM; Jackson, GH; Morgan, GJ; Navarro Coy, N; Osborne, WL; Owen, RG; Roddie, H; Ross, FM; Rudin, C; Szubert, AJ; Wu, P1
Mizuki, M; Morio, K; Tsugane, M; Uejima, E1
Carson, K; Colditz, G; Gage, B; Luo, S; Sanfilippo, KM; Tomasson, M; Vij, R; Weilbaecher, K1
Anderson, KC; Bianchi, G; Richardson, PG1
Anderson, KC; Ghobrial, IM; Laubach, JP; Munshi, NC; Nemani, N; Patel, CG; Raje, NS; Richardson, PG; Santo, L; Schlossman, RL; Scullen, TA; Yee, AJ1
Beck, JT; Bilic, S; Isaacs, R; Iyer, SP; Kelly, KR; Munshi, NC; Sen, S; Shah, J; Stewart, AK1
Felsenberg, D; Gabbert, TI; Hoffmeister, B1
Jaiswal, S; Noriega Aldave, AP1
Gamie, Z; Kenanidis, E; Kostakos, T; Kyrkos, J; Papamerkouriou, YM; Papavasiliou, K; Potoupnis, M; Sarris, I; Tsiridis, E1
Hashimoto, A; Horiguchi, H; Ibata, S; Iyama, S; Kamihara, Y; Kato, J; Kobune, M; Ono, K; Sato, T; Takada, K; Takimoto, R; Tatekoshi, A1
Fan, KH; Hou, J; Hu, XY; Huang, Q; Ma, J; Ren, JD; Tan, Y; Wu, J; Xiao, JR; Xiao, WJ; Zheng, W1
Chantry, AD; Evans, HR; Harris, W; Lawson, MA; Paton-Hough, JM; Ratnabalan, D; Snowden, JA; Walker, RE1
Body, JJ; Braun, A; Diel, IJ; Feng, A; Goldwasser, F; Spencer, A; Steger, G; Stopeck, AT; Vadhan-Raj, S; von Moos, R1
Abe, H; Ashihara, E; Hirai, H; Kanai, M; Kimura, S; Maekawa, T; Miida, T; Munaka, T; Nakagawa, S; Nakagawa, Y; Shoji, S; Yamato, S1
Abellá, E; Bargay, J; Blanchard, MJ; de la Rubia, J; García-Sanz, R; Gironella, M; Granell, M; Hernández, MT; Mateos, MV; Moreno, MJ; Ocio, EM; Oriol, A; Palomera, L; Payer, AR; Ribas, P; Ribera, JM; San Miguel, JF; Teruel, AI1
Abe, M; Miki, H; Nakamura, S1
Agarwal, A; Aung, TT; Strand, AO1
Anderson, KC; Argonza-Aviles, E; Badros, A; Ericson, SG; Hadala, JT; Montgomery, CW; Munshi, N; Orlowski, R; Raje, N; Vescio, R; Warsi, G1
Alexeeva, Y; Balakumaran, A; Braun, A; Facon, T; Feng, A; Hungria, V; Raje, N; Roodman, GD; Spencer, A; Stewart, AK; Terpos, E; Vadhan-Raj, S; Willenbacher, W1
Ding, K; Ding, S; Fu, R; Guan, J; Li, L; Liu, H; Liu, Z; Peng, F; Qu, W; Ruan, E; Shao, Z; Song, J; Wang, G; Wang, H; Wang, X; Wang, Y; Wu, Y; Xing, L1
Mohamed, M1
De Angelis, G; Ferretti, A; Petrucci, MT1
Bonanini, M; Fornaini, C; Giovannacci, I; Manfredi, M; Meleti, M; Merigo, E; Vescovi, P1
Abe, M; Aihara, K; Amachi, R; Bat-Erdene, A; Cui, Q; Endo, I; Fujii, S; Harada, T; Iwasa, M; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Oda, A; Ozaki, S; Sogabe, K; Teramachi, J; Yoshida, S1
Foster, JC; Go, RS; Grubbs, SS; Himelstein, AL; Khatcheressian, JL; Loprinzi, CL; Novotny, PJ; O'Connor, T; O'Mara, A; Qin, R; Roberts, JD; Seisler, DK; Shapiro, CL; Velasco, MR; Weckstein, D1
Fu, R; Gao, S; Jiang, F; Li, L; Liu, H; Liu, Z; Peng, F; Ruan, E; Shao, Z; Song, J; Wang, G1
Avilès, A; Cleto, S; Huerta-Guzmàn, J; Nambo, MJ; Neri, N1
Gallego, L; Junquera, L1
Andriani, A; Balleari, E; Boccadoro, M; Bongarzoni, V; Bringhen, S; Caravita, T; D'Arena, G; Guglielmelli, T; Musto, P; Palumbo, A; Petrucci, MT; Pietrantuono, G1
Bamia, C; Bamias, A; Christoulas, D; Dimopoulos, MA; Eleftherakis-Papaiakovou, E; Gika, D; Kastritis, E; Melakopoulos, I; Migkou, M; Roussou, M; Terpos, E1
Chen, Q; Dong, M; Feng, FY; Feng, JF; Jiao, SC; Li, J; Liu, JW; Ren, J; Song, ST; Wang, XW; Wang, YJ; Wang, ZH; Xie, GR; Xu, N; Zhang, Y; Zhou, QH1
Gallego, L; Junquera, L; Villarreal, P1
Abildgaard, N; Gregersen, H; Lund, T; Marker, P; Vangsted, A1
Almojaly, SA; Berk, J; Dziak, R; Goodloe Iii, S; Margarone Iii, J; Rao, MV; Sullivan, M1
Grasko, JM; Herrmann, RP; Vasikaran, SD1
Khan, AM; Sindwani, R1
Aki, SZ; Cetiner, M; Cetiner, S; Gultekin, SE; Haznedar, R; Kahraman, SA; Kocakahyaoglu, B; Sucak, GT1
Abe, Y; Goto, S; Kaneko, T; Muto, M; Nakagawa, Y; Nicol, A; Nieda, M; Suzuki, K; Yokokawa, K1
Bakker, F; Baum, W; Burger, R; Gordon, S; Gramatzki, M; Green, JR; Guenther, A; Roelofs, AJ; Rogers, MJ; Tiemann, M1
Ando, R; Fukami, K; Hashiguchi, M; Hazama, T; Koike, K; Morishige, S; Nagano, M; Nishida, H; Okuda, S; Taguchi, K; Tamaki, K; Ueda, S; Yoshimura, J1
Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K1
Crawford, BS; Kraut, EH; McNulty, RM; Turowski, RC1
D'Auria, F; Dammacco, F; Di Pietro, G; Ditonno, P; Gnoni, A; Guarini, A; Mangialardi, G; Moschetta, M; Musto, P; Ria, R; Ribatti, D; Ricciardi, MR; Vacca, A1
Ameratunga, R; Chiu, W; Oei, P; Pullon, H; The, R; Woon, ST1
Bernardeschi, P; D'Alessandro, M; Del Conte, A; Fiorentini, G; La Ferla, F; Montagnani, F; Turrisi, G1
Berenson, J; Coleman, RE; Cook, RJ; Lipton, A; Terpos, E1
Anargyrou, K; Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Kokkoris, P; Migkou, M; Terpos, E; Tsionos, K1
Abildgaard, N; Delaisse, JM; Lund, T; Plesner, T1
Berenson, JR7
Hohl, RJ; Holstein, SA1
Altundag, K; Ararat, E; Ozdemir, E; Sahin, I1
Abeltino, M; Agnelli, L; Bolzoni, M; Bonomini, S; Colla, S; Giuliani, N; Neri, A; Rizzoli, V; Storti, P; Todoerti, K1
Berenson, JR; Bolejack, V; Crowley, J; Farber, CM; Flinn, IW; Gravenor, DS; Hilger, JD; Makary, A; Morganstein, N; Nassir, Y; Sanani, S; Sefaradi, A; Shamouelian, A; Staszewski, H; Swift, RA; Tiffany, NM; Upadhyaya, GH; Yang, HH; Yellin, O1
Ashcroft, AJ; Bell, SE; Byrne, J; Child, JA; Cocks, K; Cook, G; Davies, FE; Drayson, MT; Feyler, S; Gregory, WM; Jackson, GH; Morgan, GJ; Navarro-Coy, N; Owen, RG; Roddie, H; Ross, F; Rudin, C; Szubert, AJ1
Rajkumar, SV2
Brandi, ML; Cavalli, L; Cavalli, T; Falchetti, A; Marini, F; Masi, L; Tonelli, P1
Nathan, C; Phillips, JM; Thibodeaux, JD1
Arduino, PG; Battaglio, C; Berardi, D; Broccoletti, R; Chiecchio, A; Donadio, M; Gandolfo, S; Menegatti, E; Mozzati, M; Scoletta, M; Scully, C; Vandone, AM1
Gnanapandithan, K; Kumar, S; Malhotra, P; Sharma, A; Singh, S; Varma, S1
Costa, L; Dansey, R; Goldwasser, F; Henry, DH; Hirsh, V; Hungria, V; Jiang, Q; Jun, S; Prausova, J; Scagliotti, GV; Sleeboom, H; Spencer, A; Vadhan-Raj, S; von Moos, R; Wang, J; Willenbacher, W; Woll, PJ; Yeh, H1
Terpos, E1
Berenson, J; Dimopoulos, MA; Terpos, E1
Morgan, GJ2
Green, JR; Guenther, A1
Fukami, K; Koike, K; Morishige, S; Okamura, T; Okuda, S; Taguchi, K; Yakushiji, K1
Burkley, B; Casanova, O; Ferreira, P; Gong, Y; Hou, W; Katz, J; Langaee, TY; Moreb, JS; Salmasinia, D1
Abbruzzese, A; Ascani, R; Calimeri, T; Caraglia, M; Cigliana, G; De Rosa, G; Franco, R; La Rotonda, MI; Leonetti, C; Liguori, G; Marra, M; Salzano, G; Scarsella, M; Tagliaferri, P; Tassone, P; Zappavigna, S1
Pozzi, S; Raje, N1
Ludwig, H; Zojer, N1
Arbitrio, M; Baudi, F; Calimeri, T; Cannataro, M; Cucinotto, I; Di Martino, MT; Guzzi, PH; Leone, E; Piro, E; Prantera, T; Rossi, M; Tagliaferri, P; Tassone, P; Veltri, P1
Lockhart, AC; Sorscher, SM1
Abe, M; Amou, H; Cui, Q; Fujii, S; Harada, T; Hiasa, M; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Oda, A; Ozaki, S; Shibata, H; Takeuchi, K; Watanabe, K; Yata, K1
Bensimon, AG; Ericson, SG; Guo, A; Marynchenko, M; Namjoshi, M; Raje, N; Wu, EQ; Yu, AP1
Kyrgidis, A; Tzellos, TG1
Kami, M; Matayoshi, T; Takeuchi, K; Tanimoto, T; Yagasaki, F1
Boccadoro, M; Bosia, A; Canepari, ME; Castella, B; Coscia, M; Fiore, F; Foglietta, M; Massaia, M; Palumbo, A; Pantaleoni, F; Peola, S; Riganti, C1
Ashcroft, AJ; Bell, SE; Byrne, J; Child, JA; Cocks, K; Cook, G; Davies, FE; Drayson, MT; Feyler, S; Gregory, WM; Jackson, GH; Morgan, GJ; Navarro-Coy, N; Owen, RG; Roddie, H; Ross, FM; Rudin, C; Szubert, AJ; Wu, P1
Dimopoulos, MA; Terpos, E1
Lipton, A1
Jacobs, I; Lipton, A1
Curi, MM; Lascala, CA; Marques, MM; Martins, MA; Martins, MD; Migliorati, CA; Tenis, CA1
Hewson, ID1
Anderson, KC; Ghobrial, IM; Laubach, JP; Mahindra, A; Mitsiades, CS; Munshi, N; Raje, N; Richardson, PG; Rosenblatt, J; Schlossman, RL1
Adamo, D; Aria, M; Fortuna, G; Leuci, S; Mignogna, MD; Orabona, GD; Pollio, A; Ruoppo, E1
Chen, Y; Kim, K; Kim, YK; Pai, VR; Srivastava, A; Suh, C; Teoh, G; Yoon, SS1
Bains, M; Chandiwana, D; Delea, TE; El Ouagari, K; Kaura, S; Morgan, GJ; Rotter, J; Taylor, M1
De Stefano, V; Logroscino, CA; Proietti, L; Scaramuzzo, L; Tamburrelli, FC1
Iida, S1
Henk, HJ; Kaura, S; Perez, JR; Teitelbaum, A1
Ashcroft, AJ; Bell, SE; Child, JA; Davies, FE; Drayson, MT; Gregory, WM; Jackson, GH; Morgan, GJ; Owen, RG; Szubert, AJ1
Morgan, G1
Clark, OA; Djulbegovic, B; Glasmacher, A; Kumar, A; Mhaskar, R; Miladinovic, B; Redzepovic, J; Wheatley, K1
Bruscino-Raiola, F; Hewson, I; Syme, D1
Freiberger, JJ; Kraft, KH; McGraw, T; Moon, RE; Padilla-Burgos, R; Piantadosi, CA; Stolp, BW; Suliman, HB1
Canuto, RA; Carossa, S; Maggiora, M; Martinasso, G; Mozzati, M; Muzio, G; Oraldi, M; Scoletta, M; Zambelli, M1
Dispenzieri, A; Gertz, MA; Greipp, PR; Hassoun, H; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, KM; Lust, JA; Mandrekar, SJ; Rajkumar, SV; Reeder, CB; Roy, V; Witzig, TE1
Edwards, CM; Edwards, JR; Lwin, ST; Mundy, GR; Yang, X; Zhang, J; Zhuang, J1
Locke, FL; Morgan, GJ1
Kamoh, AK; Ogle, O1
Suzuki, K1
McCarthy, PL1
Cha, YJ; Lee, YJ1
Collet, P; Marotte, H; Nizeica, V1
Anderson, K; Berenson, JR; Biermann, JS; Hillner, BE; Kyle, RA; Lipton, A; Yee, GC1
Forciniti, S; Galea, E; Tagliaferri, P; Tassone, P; Venuta, S1
Cohen, MH; Dagher, R; Griebel, DJ; Ibrahim, A; Martin, A; Pazdur, R; Scher, NS; Sokol, GH; Williams, GA1
Culligan, DJ; Gordon, S; Greaves, M; Helfrich, MH; Ralston, SH; Rogers, MJ; Sati, HI; Soutar, RL1
Dolan, G; Jones, SG; Lengyel, K; Myers, B1
Gleason, D; Gordon, D; Kowalski, MO; Lipton, A; Reitsma, D; Rosen, L; Saad, F; Seaman, J; Small, E; Smith, M1
Croucher, PI; De Hendrik, R; Green, J; Hijzen, A; Lippitt, J; Perry, MJ; Shipman, CM; Van Camp, B; Van Marck, E; Vanderkerken, K1
Ashcroft, AJ; Davies, FE; Morgan, GJ1
Gimsing, P; Jurlander, J; Nielsen, LB; Salomo, M1
Booth, B; Chen, G; Gobburu, JV; Hsieh, Y; Ibrahim, A; Leighton, J; Li, N; Pazdur, R; Rahman, A; Scher, N; Sridhara, R; Vause, D; Williams, G; Wood, R1
Arcara, C; Caccamo, N; Di Sano, C; Dieli, F; Fulfaro, F; Gebbia, N; Meraviglia, S; Montesano, C; Poccia, F; Salerno, A; Sireci, G; Valerio, MR1
Apffelstaedt, J; Belch, A; Chen, BL; Coleman, RE; Gordon, D; Howell, A; Hussein, MA; Kaminski, M; Mackey, J; Reitsma, DJ; Rosen, LS; Seaman, JJ1
Hohneker, J; Lacerna, L1
Avcu, F; Nevruz, O; Pekel, A; Sengul, A; Ural, AU; Yalcin, A; Yilmaz, MI; Zerman, M1
Khaira, NS; Sekhon, JS; Singh, D1
Decker, JL; Henderson, C; Hohneker, JA; Kaplan, BH; Lacerna, L; Orlowski, R; Purdy, MH; Schnell, FM; Vogel, CL; Wood, AJ; Yanagihara, RH1
Algur, E; Häfeli, UO; Macklis, RM1
Inoue, K; Kawada, K; Minami, H; Okabe, K; Sasaki, T; Sawamura, M; Takashima, S; Watanabe, T; Yagi, Y1
Coleman, RE; Glendenning, GA; Radeva, JI; Reed, SD; Schulman, KA1
Bertieri, R; Boano, L; Boccadoro, M; Bruno, B; Castella, B; Coscia, M; Fiore, F; Foglietta, M; Mariani, S; Massaia, M; Muraro, M; Nuschak, B; Palumbo, A; Pantaleoni, F; Peola, S1
Antonioli, E; Bosi, A; Ficarra, G; Vannucchi, AM1
Chou, T1
Beilin, J; Ingram, KB; Nguyen, HV1
Crowley, J; Durie, BG; Katz, M1
Duck, L; Maerevoet, M; Martin, C1
Avcu, F; Ural, AU4
Corso, A; Ferretti, E; Lazzarino, M1
Corradi, D; Manfredi, M; Meleti, M; Merigo, E; Vescovi, P1
Broumand, V; Fortin, M; Marx, RE; Sawatari, Y1
Fietkau, R; Gundlach, KK; Lenz, JH; Mueller, PC; Schmidt, W; Steiner-Krammer, B1
Cull, G; Henley, D; Kaye, J; Walsh, J1
Anagnostopoulos, A; Bamia, C; Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Koutsoukou, V; Melakopoulos, I; Moulopoulos, LA; Papadimitriou, C; Terpos, E1
Vastag, B1
Etayo-Pérez, A; Garatea-Crelgo, J; Martino-Gorbea, R; Pastor-Zuazaga, D; Sebastián-López, C1
Baccarani, M; Boni, P; Cangini, D; Cavo, M; Ceccolini, M; Cellini, C; Parente, R; Perrone, G; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E1
Bishop, PA; Hay, KD1
Dimitrakopoulos, I; Karakasis, D; Magopoulos, C1
Elting, LS; Migliorati, CA; Siegel, MA1
Anagnostopoulos, A; Bamia, C; Bamias, A; Dimopoulos, MA; Gika, D; Kastritis, E; Melakopoulos, I; Moulopoulos, LA; Terpos, E; Tsionos, K1
Bemardeschi, P; Dentico, P; Fiorentini, G; Giustarini, G; Rossi, S; Turano, E1
Gregersen, H; Neumann, B1
Biasotto, M; Cavalli, F; Chiandussi, S; Cova, MA; Di Lenarda, R; Dore, F1
Bergsagel, PL; Carr, AB; Dalton, RJ; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Gollbach, KL; Greipp, PR; Hayman, SR; Kademani, D; Keller, EE; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Stewart, AK; Viozzi, CF; Witzig, TE; Zeldenrust, SR1
Baumann, P; Emmerich, B; Meinhardt, G; Schmidmaier, R; Simsek, M1
Baumann, A; Czerny, C; Eisenmenger, G; Ewers, R; Hoffmann, M; Moser, D; Pietschmann, P; Wutzl, A1
Baulch-Brown, C; Ma, D; Molloy, TJ; Spencer, A; Yeh, SL1
Badros, A; Benderson, D; Karakunnel, J; Kathuria, S1
McKenna, KE; Morris, TC; Ramadan, KM1
Anagnostopoulos, A; Chantry, A; Croucher, PI; Dimopoulos, MA; Heath, DJ; Katodritou, E; Pouli, A; Rahemtulla, A; Terpos, E; Verrou, E; Vervessou, EC; Zervas, K1
Baccarani, M; Brioli, A; Cangini, D; Catalano, L; Cavo, M; Ceccolini, M; Cellini, C; D'Arco, A; Di Raimondo, F; Offidani, M; Perrone, G; Ronconi, S; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E1
Avanzati, A; Gennari, L; Gozzetti, A; Lauria, F; Martini, G; Nuti, R1
Battley, J; Jayathissa, S; Seneviratne, E1
Calvo-Villas, JM; Carreter de Granda, E; Govantes Rodríguez, J; Sicilia Guillén, F; Tapia Torres, M1
Barnett, JB; de Lemos, ML; Hu, F; Levin, A; Moravan, V; O'Reilly, SE; Taylor, SC1
Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E1
Agurto P, J; Anguita C, T; Laissle C, G; Roa E, I1
Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E1
Agazzi, A; D'Orto, O; Derada Troletti, G; Diego, R; Fontanella, W; Marzano, U; Pagani, D; Pignataro, L1
Araújo, SR; Cossolin, GS; Curi, MM; dos Santos, MO; Feher, O; Koga, DH; Zardetto, C1
Blasick, TM; Brown, RE; Quiery, AT; Zhang, PL1
Anaissie, EJ; Boyette, J; Clarke, BM; Stack, BC; Suen, JY; Vural, E1
de Visscher, JG; Schortinghuis, J; Spijkervet, KL; Witjes, MJ1
Corso, A; Klersy, C; Lazzarino, M; Mangiacavalli, S; Pica, G; Varettoni, M; Zappasodi, P1
Fantini, M; Nicoletti, S; Poggi, B; Possenti, C; Sartori, S; Tamburini, E; Tassinari, D1
Barlogie, B; Elici, F; Gokden, N; Kumar, J; Zangari, M1
Bodmer, M; Kummer, O; Ramazzina, C; Rätz Bravo, AE; Zysset Aschmann, Y1
Amico, P; Bodmer, M; Haschke, M; Krähenbühl, S; Kummer, O; Mayr, M; Mihatsch, MJ1
Berenson, JR; Coleman, RE; Cook, RJ; Lipton, A; Major, P; Smith, MR; Terpos, E1
Briones, DL; Ferres, AJ; Herbozo, PJ; Torrealba, RL1
Alpay, N; Ayer, M; Küçükkaya, RD; Mete, O; Nalçaci, M; Yavuz, AS; Yenerel, MN; Yildirim, ND1
Kouvaris, C; Mouzopoulos, D; Mouzopoulos, G; Stamatakos, M; Tzurbakis, M1
Crawford, B; Gibson, J; Iland, H; Joshua, D; Joy Ho, P; Sanders, J1
Avilés, A; Castañeda, C; Cleto, S; Huerta-Guzmán, J; Nambo, MJ; Neri, N1
Cho, R; Koizumi, M; Nakaseko, C; Nishimura, M; Ohwada, C; Ozawa, S; Saito, Y; Shimizu, N; Takeuchi, M1
Coleman, RE; Cook, RJ; Lipton, A; Major, P; Smith, MR1
Guthmiller, JM; Humbert, LA; Johnson, GK; Statz, TA1
Bonneterre, J; Cortet, B; Facon, T; Maes, JM; Magro, L; Penel, G; Vieillard, MH1
Bostan, F; Ozkaynak, C; Timurağaoğlu, A; Tuzuner, S; Undar, L1
Botelho, C; Cavaleiro, MV; Cortez, PP; Hussain, NS; Lobato, JV; Maurício, AC; Rodrigues, JM; Santos, JD; Xavier, L1
Bertieri, R; Boccarelli, A; Cirulli, T; Coluccia, AM; Coluccia, M; Dammacco, F; Di Pietro, G; Giannini, T; Mangialardi, G; Ribatti, D; Scavelli, C; Vacca, A1
Cabezas Macián, A; Gutiérrez Pérez, JL; Infante Cossío, P; Palomino Nicas, J; Pérez Ceballos, JL1
Bedogni, A; Bedogni, G; Blandamura, S; Chiarini, L; Ferrari, F; Ferretti, M; Ferronato, G; Lo Muzio, L; Lo Russo, L; Lokmic, Z; Ninfo, V; Nocini, PF; Palumbo, C; Pietrogrande, F; Procopio, O; Ragazzo, M; Saia, G; Tregnaghi, A1
McKeage, K; Plosker, GL1
Dhillon, S; Lyseng-Williamson, KA1
Caruso, PA; Dodson, TB; Raje, NS; Rosenberg, AE1
Bilic, S; Copeman, M; Cremers, S; Kennedy, N; Lynch, K; Neeman, T; Ravera, C; Roberts, A; Schran, H; Spencer, A1
Avanzati, A; Campagna, MS; De Paola, V; Franci, B; Gennari, L; Gozzetti, A; Lauria, F; Marchini, E; Martini, G; Merlotti, D; Nuti, R; Salvadori, S; Tozzi, M1
Andriani, A; Barbarano, L; Bibas, M; Cafro, AM; D'Avanzo, G; Gaglioti, D; Morra, E; Nichelatti, M; Nosari, AM; Riva, F; Taroni, A1
Delmas, PD1
Aparicio, A; Berenson, J; Gardner, A; Lichtenstein, A; Savage, A; Tu, Y1
Berenson, J; Hortobagyi, G; Lipton, A; Major, PP1
Amiot, M; Barillé, S; Bataille, R; Berthaud, P; Collette, M; Derenne, S; Harousseau, JL; Robillard, N1
Forciniti, S; Galea, E; Martinelli, V; Morrone, G; Tagliaferri, P; Tassone, P; Turco, MC; Venuta, S1
Berenson, JR; Coleman, RE; Dreicer, R; Howell, A; Kuross, SA; Lipton, A; Morley, W; Porter, L; Rosen, LS; Seaman, JJ1
Ali, SM; Costa, L; Esteva, FJ; Harvey, H; Hortobagyi, G; Knight, R; Lipton, A; Seaman, J1
Hussein, MA; Juturi, JV; Lieberman, I1
Barlogie, B; Choi, Y; Epstein, J; Johnson, CL; Pearse, RN; Yaccoby, S1

Reviews

51 review(s) available for zoledronic acid and Kahler Disease

ArticleYear
A systematic review and meta-analysis of interventional studies of bisphosphonates and denosumab in multiple myeloma and future perspectives.
    Journal of musculoskeletal & neuronal interactions, 2022, 12-01, Volume: 22, Issue:4

    Topics: Clodronic Acid; Denosumab; Diphosphonates; Humans; Multiple Myeloma; Zoledronic Acid

2022
Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents.
    Journal of bone and mineral metabolism, 2023, Volume: 41, Issue:3

    Topics: Bone and Bones; Bone Diseases; Cytokines; Humans; Multiple Myeloma; Tumor Microenvironment; Zoledronic Acid

2023
A Patient with a History of Multiple Myeloma Presents for the Evaluation of Oral Lesion and Burning Sensation of the Mouth.
    Dental clinics of North America, 2023, Volume: 67, Issue:4

    Topics: Face; Humans; Mouth; Multiple Myeloma; Pain; Zoledronic Acid

2023
Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials.
    Clinical therapeutics, 2020, Volume: 42, Issue:8

    Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Humans; Multiple Myeloma; Randomized Controlled Trials as Topic; Zoledronic Acid

2020
Controversies in the use of new bone-modifying therapies in multiple myeloma.
    British journal of haematology, 2021, Volume: 193, Issue:6

    Topics: Bone Density Conservation Agents; COVID-19; Denosumab; Diphosphonates; Humans; Hypercalcemia; Multiple Myeloma; Osteolysis; Receptor Activator of Nuclear Factor-kappa B; Renal Insufficiency; Zoledronic Acid

2021
Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials.
    Journal of orthopaedic surgery and research, 2021, Jun-22, Volume: 16, Issue:1

    Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Humans; Multiple Myeloma; Plasmacytoma; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid

2021
Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
    Future oncology (London, England), 2018, Volume: 14, Issue:3

    Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Neoplasms; Osteoclasts; RANK Ligand; Treatment Outcome; Zoledronic Acid

2018
Bisphosphonates in multiple myeloma: an updated network meta-analysis.
    The Cochrane database of systematic reviews, 2017, 12-18, Volume: 12

    Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Disease-Free Survival; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid

2017
Management of multiple myeloma bone disease: impact of treatment on renal function.
    Expert review of hematology, 2018, Volume: 11, Issue:11

    Topics: Bone Density Conservation Agents; Bone Diseases; Disease Management; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Multiple Myeloma; Osteolysis; Practice Guidelines as Topic; Zoledronic Acid

2018
Bisphosphonates for Patients Diagnosed With Multiple Myeloma.
    JAMA, 2018, 10-09, Volume: 320, Issue:14

    Topics: Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Randomized Controlled Trials as Topic; Review Literature as Topic; Zoledronic Acid

2018
Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
    Frontiers in immunology, 2018, Volume: 9

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Bone Diseases; Bone Morphogenetic Proteins; Bortezomib; Genetic Markers; Humans; Mice; Multiple Myeloma; Osteocytes; Osteogenesis; Osteolysis; Zoledronic Acid

2018
Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?
    Expert review of hematology, 2019, Volume: 12, Issue:8

    Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Bone Density Conservation Agents; Bone Diseases; Denosumab; Humans; Multiple Myeloma; RANK Ligand; Zoledronic Acid

2019
[Inhibition of RANK ligand to treat bone metastases].
    Bulletin du cancer, 2013, Volume: 100, Issue:11

    Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid

2013
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Dec-15, Volume: 19, Issue:24

    Topics: Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Neoplasm Metastasis; Pamidronate; Prostatic Neoplasms; Zoledronic Acid

2013
Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review.
    European journal of haematology, 2014, Volume: 92, Issue:3

    Topics: Antineoplastic Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Drug Monitoring; Humans; Ibandronic Acid; Imidazoles; Multiple Myeloma; Pamidronate; Zoledronic Acid

2014
Treatment of multiple myeloma bone disease: experimental and clinical data.
    Expert opinion on biological therapy, 2015, Volume: 15, Issue:2

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Quality of Life; Zoledronic Acid

2015
Therapeutic options in the management of myeloma bone disease.
    Seminars in oncology, 2010, Volume: 37 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases; Clinical Trials as Topic; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Zoledronic Acid

2010
Skull base osteomyelitis and bisphosphonate use in multiple myeloma: report of two cases and literature review.
    The Laryngoscope, 2010, Volume: 120 Suppl 4

    Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteomyelitis; Retrospective Studies; Skull Base; Tomography, X-Ray Computed; Zoledronic Acid

2010
Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
    Critical reviews in oncology/hematology, 2011, Volume: 77 Suppl 1

    Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Mice; Multiple Myeloma; Osteolysis; Pamidronate; Risk Factors; Spinal Cord Compression; Zoledronic Acid

2011
Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?
    Critical reviews in oncology/hematology, 2011, Volume: 77 Suppl 1

    Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Breast Neoplasms; Clodronic Acid; Diphosphonates; Drug Evaluation, Preclinical; Female; Humans; Imidazoles; Male; Mice; Multiple Myeloma; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Treatment Outcome; Zoledronic Acid

2011
The backbone of progress--preclinical studies and innovations with zoledronic acid.
    Critical reviews in oncology/hematology, 2011, Volume: 77 Suppl 1

    Topics: Animals; Apoptosis; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Imidazoles; Mice; Multiple Myeloma; Neovascularization, Pathologic; Osteoclasts; Zoledronic Acid

2011
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.
    The oncologist, 2011, Volume: 16, Issue:5

    Topics: Acute-Phase Reaction; Bone Diseases; Diphosphonates; Endothelial Cells; Humans; Imidazoles; Multiple Myeloma; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronate; Practice Guidelines as Topic; Zoledronic Acid

2011
Supportive therapy in multiple myeloma.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 183

    Topics: Anemia; Blood Transfusion; Bone Diseases; Calcitonin; Clodronic Acid; Diphosphonates; Erythropoietin; Fractures, Bone; Hematinics; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Osteoporosis; Pamidronate; Recombinant Proteins; Renal Insufficiency; Zoledronic Acid

2011
Zoledronic acid: multiplicity of use across the cancer continuum.
    Expert review of anticancer therapy, 2011, Volume: 11, Issue:7

    Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Neoplasms; Zoledronic Acid

2011
Antitumor effects of bisphosphonates: from the laboratory to the clinic.
    Current opinion in supportive and palliative care, 2011, Volume: 5, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Breast Neoplasms; Cell Adhesion Molecules; Diphosphonates; Female; Humans; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Zoledronic Acid

2011
Denosumab: benefits of RANK ligand inhibition in cancer patients.
    Current opinion in supportive and palliative care, 2011, Volume: 5, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Multiple Myeloma; RANK Ligand; Zoledronic Acid

2011
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
    European journal of haematology, 2012, Volume: 88, Issue:1

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Multiple Myeloma; Osteolysis; Practice Guidelines as Topic; Zoledronic Acid

2012
[Multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Denosumab; Diphosphonates; Humans; Imidazoles; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Zoledronic Acid

2012
Bisphosphonates in multiple myeloma: a network meta-analysis.
    The Cochrane database of systematic reviews, 2012, May-16, Issue:5

    Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid

2012
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
    Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012

    Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; Humans; Imidazoles; In Situ Hybridization, Fluorescence; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Proteinuria; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Time Factors; Translocation, Genetic; Treatment Outcome; Zoledronic Acid

2012
Current therapeutic strategy for multiple myeloma.
    Japanese journal of clinical oncology, 2013, Volume: 43, Issue:2

    Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid

2013
Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1

    Topics: Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Zoledronic Acid

2013
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
    Cancer investigation, 2002, Volume: 20 Suppl 2

    Topics: Adenocarcinoma; Biomarkers; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteolysis; Osteoporosis; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Safety; Zoledronic Acid

2002
Advances in the biology and treatment of myeloma bone disease.
    Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 17

    Topics: Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Clinical Trials as Topic; Cytokines; Diphosphonates; Endothelial Growth Factors; Glycoproteins; Humans; Imidazoles; Immunoglobulin Fc Fragments; Intercellular Signaling Peptides and Proteins; Lymphokines; Membrane Glycoproteins; Multiple Myeloma; Osteoprotegerin; Pamidronate; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Zoledronic Acid

2002
Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis.
    Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:4

    Topics: Animals; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Osteoporosis; Randomized Controlled Trials as Topic; Zoledronic Acid

2003
Aetiology of bone disease and the role of bisphosphonates in multiple myeloma.
    The Lancet. Oncology, 2003, Volume: 4, Issue:5

    Topics: Antineoplastic Agents; Bone and Bones; Bone Density; Bone Neoplasms; Chemokines; Clinical Trials as Topic; Clodronic Acid; Cytokines; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Osteolysis; Patient Selection; Treatment Outcome; Zoledronic Acid

2003
Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors.
    Seminars in oncology, 2003, Volume: 30, Issue:5 Suppl 16

    Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Multiple Myeloma; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid

2003
Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease.
    Seminars in hematology, 2003, Volume: 40, Issue:4 Suppl 4

    Topics: Adjuvants, Immunologic; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Life Tables; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Treatment Outcome; Zoledronic Acid

2003
[Multiple myeloma--recent advances in diagnosis and treatment].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Multiple Myeloma; Neoplasm Staging; Pamidronate; Protease Inhibitors; Pyrazines; Thalidomide; Zoledronic Acid

2005
Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.
    Hematology (Amsterdam, Netherlands), 2005, Volume: 10, Issue:3

    Topics: Animals; Bone Marrow; Bone Marrow Cells; Cell Proliferation; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Osteoclasts; Plasma Cells; Signal Transduction; Stromal Cells; Zoledronic Acid

2005
Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment.
    The Lancet. Oncology, 2006, Volume: 7, Issue:6

    Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Dental Care for Chronically Ill; Diphosphonates; Humans; Imidazoles; Jaw; Mandibular Diseases; Multiple Myeloma; Osteonecrosis; Pamidronate; Practice Guidelines as Topic; Time Factors; Zoledronic Acid

2006
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.
    Mayo Clinic proceedings, 2006, Volume: 81, Issue:8

    Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Minnesota; Multiple Myeloma; Osteoporosis; Pamidronate; Practice Guidelines as Topic; Zoledronic Acid

2006
Scleritis complicating zoledronic acid infusion.
    Clinical lymphoma & myeloma, 2006, Volume: 7, Issue:2

    Topics: Aged; Anti-Inflammatory Agents; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Multiple Myeloma; Pamidronate; Radiography; Scleritis; Zoledronic Acid

2006
[Zoledronate-associated end stage renal failure and hypocalcaemia].
    Praxis, 2007, Apr-25, Volume: 96, Issue:17

    Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Biopsy; Bone Density Conservation Agents; Calcium; Creatinine; Diphosphonates; Disease Progression; Female; Follow-Up Studies; Humans; Hypocalcemia; Imidazoles; Kidney Failure, Chronic; Kidney Tubules; Middle Aged; Multiple Myeloma; Pamidronate; Renal Dialysis; Risk Factors; Switzerland; Time Factors; Vitamin D; Zoledronic Acid

2007
Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma.
    Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:5

    Topics: Biomarkers; Bone and Bones; Bone Neoplasms; Diphosphonates; Disease Progression; Humans; Imidazoles; Multiple Myeloma; Osteolysis; Predictive Value of Tests; Risk Factors; Survival Rate; Zoledronic Acid

2007
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    PharmacoEconomics, 2008, Volume: 26, Issue:3

    Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Quality-Adjusted Life Years; Zoledronic Acid

2008
Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
    Drugs, 2008, Volume: 68, Issue:4

    Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid

2008
Clinical research update: zoledronate.
    Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl

    Topics: Animals; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Mice; Multiple Myeloma; Rats; Zoledronic Acid

1997
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
    Cancer, 2000, Jan-01, Volume: 88, Issue:1

    Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid

2000
Advances in the biology and treatment of myeloma bone disease.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2001, Nov-15, Volume: 58 Suppl 3

    Topics: Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Zoledronic Acid

2001
Multiple myeloma: present and future.
    Current opinion in oncology, 2002, Volume: 14, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Oxides; Pamidronate; Thalidomide; Zoledronic Acid

2002

Trials

47 trial(s) available for zoledronic acid and Kahler Disease

ArticleYear
Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis.
    Advances in therapy, 2020, Volume: 37, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Asian People; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Double-Blind Method; Female; Humans; Male; Middle Aged; Multiple Myeloma; Treatment Outcome; Zoledronic Acid

2020
Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study.
    Blood advances, 2021, 02-09, Volume: 5, Issue:3

    Topics: Aged; Denosumab; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Progression-Free Survival; Transplantation, Autologous; Zoledronic Acid

2021
Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results.
    Frontiers in immunology, 2020, Volume: 11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Disease Progression; Female; Humans; Interleukin-2; Italy; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Remission Induction; Time Factors; Treatment Outcome; Zoledronic Acid

2020
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
    The Lancet. Oncology, 2018, Volume: 19, Issue:3

    Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Double-Blind Method; Female; Fractures, Spontaneous; Humans; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Risk Factors; Spinal Cord Compression; Time Factors; Treatment Outcome; Zoledronic Acid

2018
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
    Journal of medical economics, 2018, Volume: 21, Issue:5

    Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Cost of Illness; Cost-Benefit Analysis; Denosumab; Diphosphonates; Female; Health Expenditures; Humans; Imidazoles; Male; Models, Economic; Multiple Myeloma; Quality-Adjusted Life Years; Survival Analysis; United States; Zoledronic Acid

2018
Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study.
    British journal of haematology, 2018, Volume: 182, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clodronic Acid; Consolidation Chemotherapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Quality of Life; Remission Induction; Self Report; Surveys and Questionnaires; Thalidomide; Transplantation, Autologous; Young Adult; Zoledronic Acid

2018
Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2013, Volume: 28, Issue:8

    Topics: Age Factors; Aged; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Peptides; Radionuclide Imaging; Zoledronic Acid

2013
Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Zoledronic Acid

2013
The impact of response on bone-directed therapy in patients with multiple myeloma.
    Blood, 2013, Oct-24, Volume: 122, Issue:17

    Topics: Adult; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Zoledronic Acid

2013
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Denosumab; Diphosphonates; Disease Progression; Double-Blind Method; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasms; Pain; Treatment Outcome; Zoledronic Acid

2014
Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer.
    Acta oncologica (Stockholm, Sweden), 2014, Volume: 53, Issue:4

    Topics: Adult; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Prospective Studies; Radioimmunoassay; Zoledronic Acid

2014
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
    British journal of haematology, 2014, Volume: 166, Issue:1

    Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Drug Administration Schedule; England; Female; Follow-Up Studies; Humans; Imidazoles; Incidence; Male; Middle Aged; Multiple Myeloma; Osteolysis; Zoledronic Acid

2014
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
    British journal of haematology, 2014, Volume: 167, Issue:3

    Topics: Aged; Anabolic Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Female; Fractures, Spontaneous; Humans; Hypertension; Imidazoles; Intercellular Signaling Peptides and Proteins; Male; Maximum Tolerated Dose; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Osteolysis; Recurrence; Spinal Cord Compression; Zoledronic Acid

2014
Zoledronic Acid may reduce intraoperative bleeding in spinal tumors: a prospective cohort study.
    BioMed research international, 2015, Volume: 2015

    Topics: Adult; Aged; Blood Loss, Surgical; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Spinal Neoplasms; Zoledronic Acid

2015
The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:11

    Topics: Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasms; Proportional Hazards Models; Zoledronic Acid

2015
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.
    Haematologica, 2015, Volume: 100, Issue:9

    Topics: Adult; Aged; Bone Diseases; Diphosphonates; Disease-Free Survival; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Survival Rate; Zoledronic Acid

2015
Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Mar-15, Volume: 22, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Diseases; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Osteolysis; Peptides; Zoledronic Acid

2016
Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.
    Blood cancer journal, 2016, Jan-08, Volume: 6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Female; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Transplantation, Autologous; Treatment Outcome; Zoledronic Acid

2016
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
    JAMA, 2017, 01-03, Volume: 317, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Prostatic Neoplasms; Sample Size; Spinal Cord Compression; Spinal Fractures; Zoledronic Acid

2017
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
    Cancer, 2008, Oct-01, Volume: 113, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Survival Analysis; Zoledronic Acid

2008
[Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:3

    Topics: Adult; Aged; Analgesics; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Colorectal Neoplasms; Creatinine; Diphosphonates; Double-Blind Method; Female; Fever; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Pain, Intractable; Pamidronate; Peptides; Prospective Studies; Vomiting; Zoledronic Acid

2008
Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.
    Experimental hematology, 2009, Volume: 37, Issue:8

    Topics: Adult; Aged; Blood Cells; Bone Density Conservation Agents; Bone Marrow Cells; Cell Culture Techniques; Diphosphonates; Female; Humans; Imidazoles; Immunotherapy, Adoptive; Interleukin-2; Killer Cells, Lymphokine-Activated; Lymphocyte Activation; Lymphocyte Count; Lymphocyte Subsets; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Receptors, Antigen, T-Cell, gamma-delta; Treatment Outcome; Zoledronic Acid

2009
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
    Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Research Design; Treatment Outcome; United Kingdom; Zoledronic Acid

2010
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Mar-20, Volume: 29, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; International Agencies; Male; Middle Aged; Multiple Myeloma; Neoplasms; RANK Ligand; Survival Rate; Treatment Outcome; Young Adult; Zoledronic Acid

2011
Safety and efficacy of zoledronic acid in multiple myeloma.
    Lancet (London, England), 2011, Jun-25, Volume: 377, Issue:9784

    Topics: Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Imidazoles; Incidence; Male; Multiple Myeloma; Osteonecrosis; Prognosis; Risk Assessment; Safety Management; Severity of Illness Index; Survival Analysis; Thromboembolism; Zoledronic Acid

2011
Safety and efficacy of zoledronic acid in multiple myeloma.
    Lancet (London, England), 2011, Jun-25, Volume: 377, Issue:9784

    Topics: Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Multiple Myeloma; Osteonecrosis; Prognosis; Risk Assessment; Safety Management; Survival Analysis; Thromboembolism; Treatment Outcome; Zoledronic Acid

2011
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.
    The Lancet. Oncology, 2011, Volume: 12, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; United Kingdom; Zoledronic Acid

2011
Multiple myeloma vs. breast cancer patients with bisphosphonates-related osteonecrosis of the jaws: a comparative analysis of response to treatment and predictors of outcome.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2012, Volume: 41, Issue:3

    Topics: Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Forecasting; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Multiple Myeloma; Pain Measurement; Proportional Hazards Models; Prospective Studies; Remission Induction; Treatment Outcome; Wound Healing; Zoledronic Acid

2012
Lower dose dexamethasone/thalidomide and zoledronic acid every 3 weeks in previously untreated multiple myeloma.
    Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Models, Biological; Multiple Myeloma; Thalidomide; Treatment Outcome; Zoledronic Acid

2012
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.
    Blood, 2012, Jun-07, Volume: 119, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Thalidomide; Zoledronic Acid

2012
What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2012, Volume: 70, Issue:7

    Topics: Aged; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Combined Modality Therapy; Debridement; Diphosphonates; Female; Follow-Up Studies; Gingiva; Humans; Hyperbaric Oxygenation; Imidazoles; Male; Multiple Myeloma; Osteoporosis; Pain Management; Pamidronate; Prospective Studies; Quality of Life; Treatment Outcome; Wound Healing; Zoledronic Acid

2012
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.
    Leukemia, 2013, Volume: 27, Issue:1

    Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imidazoles; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Survival Rate; Thalidomide; Zoledronic Acid

2013
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:7

    Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Kidney; Male; Multiple Myeloma; Neoplasm Metastasis; Placebos; Prostatic Neoplasms; Time Factors; United States; United States Food and Drug Administration; Zoledronic Acid

2003
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Cancer, 2003, Oct-15, Volume: 98, Issue:8

    Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Pamidronate; Zoledronic Acid

2003
Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.
    The oncologist, 2004, Volume: 9, Issue:6

    Topics: Aged; Arthralgia; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Creatinine; Diphosphonates; Fatigue; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Nausea; Pain; Pain Measurement; Prospective Studies; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid

2004
A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:1

    Topics: Adult; Aged; Breast Neoplasms; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Treatment Outcome; Zoledronic Acid

2005
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
    European journal of haematology, 2006, Volume: 76, Issue:5

    Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Remodeling; Bone Resorption; Collagen Type I; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Osteocalcin; Pain; Peptides; Thalidomide; Treatment Outcome; Zoledronic Acid

2006
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
    Haematologica, 2006, Volume: 91, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Risk; Time Factors; Zoledronic Acid

2006
Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eight patients previously treated with multiple myeloma.
    Journal of experimental & clinical cancer research : CR, 2003, Volume: 22, Issue:4 Suppl

    Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Sedimentation; Dexamethasone; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pamidronate; Prognosis; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Outcome; Zoledronic Acid

2003
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
    Blood, 2006, Dec-01, Volume: 108, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Retrospective Studies; Thalidomide; Zoledronic Acid

2006
Zoledronic acid treatment at home: safety data from an observational prospective trial.
    Journal of palliative medicine, 2007, Volume: 10, Issue:2

    Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Creatinine; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Home Care Services; Humans; Imidazoles; Karnofsky Performance Status; Male; Middle Aged; Multiple Myeloma; Observation; Prospective Studies; Prostatic Neoplasms; Survival Analysis; Time Factors; Zoledronic Acid

2007
Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS).
    International journal of laboratory hematology, 2007, Volume: 29, Issue:5

    Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Osteoporosis; Paraproteinemias; Zoledronic Acid

2007
Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma.
    Medical oncology (Northwood, London, England), 2007, Volume: 24, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Zoledronic Acid

2007
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
    The oncologist, 2007, Volume: 12, Issue:9

    Topics: Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Creatinine; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; Humans; Imidazoles; Injections, Intravenous; Male; Multiple Myeloma; Osteoclasts; Osteolysis; Pamidronate; Peptides; Retrospective Studies; Risk Assessment; Survival Rate; Treatment Outcome; Zoledronic Acid

2007
Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study.
    BMC clinical pharmacology, 2008, Mar-31, Volume: 8

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Diphosphonates; Female; Humans; Imidazoles; Kidney; Male; Middle Aged; Multiple Myeloma; Prednisolone; Thalidomide; Zoledronic Acid

2008
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
    Cancer, 2001, Apr-01, Volume: 91, Issue:7

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Collagen; Collagen Type I; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Pamidronate; Peptides; Zoledronic Acid

2001
Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jul-15, Volume: 19, Issue:14

    Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Osteolysis; Pamidronate; Time Factors; Zoledronic Acid

2001

Other Studies

174 other study(ies) available for zoledronic acid and Kahler Disease

ArticleYear
Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells.
    Journal of medicinal chemistry, 2012, Apr-12, Volume: 55, Issue:7

    Topics: Aminopyridines; Aniline Compounds; Antineoplastic Agents; Apoptosis; Catalytic Domain; Cell Survival; Crystallography, X-Ray; Diphosphonates; Drug Design; Extracellular Signal-Regulated MAP Kinases; Geranyltranstransferase; Hemiterpenes; Humans; Models, Molecular; Multiple Myeloma; Organophosphorus Compounds; Phosphorylation; Protein Conformation; Small Molecule Libraries; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured

2012
Unraveling the Prenylation-Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors.
    Journal of medicinal chemistry, 2018, Aug-09, Volume: 61, Issue:15

    Topics: Apoptosis; Catalytic Domain; Cell Proliferation; Enzyme Inhibitors; Geranylgeranyl-Diphosphate Geranylgeranyltransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Multiple Myeloma; Protein Prenylation; Pyrimidines; rap1 GTP-Binding Proteins

2018
Evaluation of denosumab in adult oncology patients for the prevention of skeletal related events across a large academic health system.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:1

    Topics: Adult; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Denosumab; Diphosphonates; Humans; Multiple Myeloma; Retrospective Studies; Vitamin D; Zoledronic Acid

2023
Pamidronate versus zoledronic acid for the treatment of multiple myeloma-related hypercalcemia.
    Kidney international, 2022, Volume: 101, Issue:5

    Topics: Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Pamidronate; Zoledronic Acid

2022
Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022, Volume: 30, Issue:12

    Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Humans; Incidence; Multiple Myeloma; Osteonecrosis; Prognosis; Retrospective Studies; Zoledronic Acid

2022
Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Bone Marrow; Hepatitis A Virus Cellular Receptor 2; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Programmed Cell Death 1 Receptor; Receptors, Antigen, T-Cell; T-Lymphocytes; Tumor Microenvironment; Zoledronic Acid

2022
Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma.
    Journal of bone and mineral metabolism, 2020, Volume: 38, Issue:2

    Topics: Adolescent; Adult; Aged; Bone and Bones; Bone Neoplasms; Cohort Studies; Diphosphonates; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Young Adult; Zoledronic Acid

2020
Life-threatening hypophosphataemia secondary to zoledronic acid implementation in a middle-age patient who presented with advanced osteolysis in the course of multiple myeloma.
    Endokrynologia Polska, 2020, Volume: 71, Issue:1

    Topics: Bone Density Conservation Agents; Humans; Hypophosphatemia; Male; Middle Aged; Multiple Myeloma; Osteolysis; Zoledronic Acid

2020
Multiple myeloma and chemical maxillary osteonecrosis. Can both occur simultaneously?
    Journal of stomatology, oral and maxillofacial surgery, 2020, Volume: 121, Issue:5

    Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Humans; Multiple Myeloma; Retrospective Studies; Zoledronic Acid

2020
Mesenchymal stromal cells administration for osteonecrosis of the jaw caused by bisphosphonate: report of two cases.
    Acta oncologica (Stockholm, Sweden), 2020, Volume: 59, Issue:7

    Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Male; Mesenchymal Stem Cell Transplantation; Multiple Myeloma; Zoledronic Acid

2020
Successful percutaneous treatment of bone tumors using microwave ablation in combination with Zoledronic acid infused PMMA cementoplasty.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2020, Volume: 76

    Topics: Adolescent; Adult; Aged; Bone Neoplasms; Cementoplasty; Female; Humans; Male; Microwaves; Multiple Myeloma; Pelvis; Polymethyl Methacrylate; Radiofrequency Therapy; Spine; Zoledronic Acid

2020
Safety and efficacy of bone-modifying agents among multiple myeloma patients: A retrospective cohort study.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Hypocalcemia; Middle Aged; Multiple Myeloma; Osteonecrosis; Retrospective Studies; Young Adult; Zoledronic Acid

2022
Medication-related osteonecrosis of the jaw in a patient with multiple myeloma: an unusual case with tumor in the surgical specimen.
    Oral radiology, 2022, Volume: 38, Issue:2

    Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Female; Humans; Multiple Myeloma; Pain; Zoledronic Acid

2022
Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.
    Blood, 2017, 06-29, Volume: 129, Issue:26

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies; Bone Density; Bone Morphogenetic Proteins; Cell Line, Tumor; Diphosphonates; Fractures, Bone; Genetic Markers; Humans; Imidazoles; Mice; Multiple Myeloma; Osteocytes; Osteogenesis; Tumor Cells, Cultured; Zoledronic Acid

2017
Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:10

    Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cytochrome P-450 CYP2C8; Humans; Multiple Myeloma; Polymorphism, Single Nucleotide; PPAR gamma; Risk Factors; Zoledronic Acid

2017
Removal of a sequestrum by a patient with medication-related osteonecrosis of the jaw.
    The British journal of oral & maxillofacial surgery, 2017, Volume: 55, Issue:9

    Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Multiple Myeloma; Self Care; Zoledronic Acid

2017
Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.
    Scientific reports, 2017, 12-20, Volume: 7, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Humans; MicroRNAs; Multiple Myeloma; Naphthols; Zoledronic Acid

2017
Denosumab for myeloma bone disease: ready for prime time?
    The Lancet. Oncology, 2018, Volume: 19, Issue:3

    Topics: Bone Diseases; Denosumab; Double-Blind Method; Humans; Multiple Myeloma; Zoledronic Acid

2018
Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw.
    Annals of hematology, 2018, Volume: 97, Issue:7

    Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Humans; Imidazoles; Lymphocytes; Male; MicroRNAs; Middle Aged; Monocytes; Multiple Myeloma; Osteoclasts; Osteolysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Zoledronic Acid

2018
Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:5

    Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Inflammation; Male; Middle Aged; Multiple Myeloma; Orbital Diseases; Zoledronic Acid

2019
Radiographic bone loss and the risk of medication-related osteonecrosis of the jaw (MRONJ) in multiple myeloma patients-A retrospective case control study.
    Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry, 2018, Volume: 38, Issue:6

    Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Case-Control Studies; Diphosphonates; Female; Humans; Male; Middle Aged; Multiple Myeloma; Radiography, Panoramic; Retrospective Studies; Risk Factors; Zoledronic Acid

2018
Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2019, Volume: 34, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Neoplasms, Experimental; Osteolysis; Transforming Growth Factor beta; Xenograft Model Antitumor Assays; Zoledronic Acid

2019
Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2019, Volume: 17, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Medicare; Multiple Myeloma; Pamidronate; Practice Guidelines as Topic; Retrospective Studies; SEER Program; Treatment Outcome; United States; Zoledronic Acid

2019
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy.
    Journal of medical economics, 2019, Volume: 22, Issue:8

    Topics: Bone Density Conservation Agents; Bone Diseases; Cost-Benefit Analysis; Denosumab; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Health Expenditures; Humans; Markov Chains; Models, Economic; Multiple Myeloma; Quality-Adjusted Life Years; Survival Analysis; Zoledronic Acid

2019
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jun-20, Volume: 31, Issue:18

    Topics: Administration, Intravenous; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Combined Modality Therapy; Diphosphonates; Drug Therapy, Combination; Fractures, Bone; Humans; Imidazoles; International Cooperation; Magnetic Resonance Imaging; Medical Oncology; Multiple Myeloma; Osteonecrosis; Outcome Assessment, Health Care; Pamidronate; Positron-Emission Tomography; Practice Guidelines as Topic; Radiotherapy; Tomography, X-Ray Computed; Zoledronic Acid

2013
Cell therapy in bisphosphonate-related osteonecrosis of the jaw.
    The Journal of craniofacial surgery, 2013, Volume: 24, Issue:3

    Topics: Aged; Autografts; Biocompatible Materials; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Marrow Transplantation; Bone Matrix; Bone Regeneration; Bone Substitutes; Calcium Phosphates; Debridement; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Mandibular Diseases; Multiple Myeloma; Platelet-Rich Plasma; Stem Cell Transplantation; Zoledronic Acid

2013
Hemorrhagic bullous colitis in a patient with multiple myeloma.
    Endoscopy, 2013, Volume: 45 Suppl 2 UCTN

    Topics: Aged; Amyloidosis; Antifibrinolytic Agents; Blister; Bone Density Conservation Agents; Colitis, Ischemic; Diphosphonates; Female; Gastrointestinal Hemorrhage; Humans; Imidazoles; Multiple Myeloma; Radiography; Sigmoidoscopy; Tranexamic Acid; Zoledronic Acid

2013
Management of bisphosphonate-related osteonecrosis of the jaw with a platelet-rich fibrin membrane: technical report.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2014, Volume: 72, Issue:2

    Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Blood Platelets; Diphosphonates; Fibrin; Humans; Imidazoles; Male; Membranes, Artificial; Multiple Myeloma; Pamidronate; Zoledronic Acid

2014
Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.
    Cell death & disease, 2013, Oct-24, Volume: 4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Diphosphonates; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Hydroxamic Acids; Imidazoles; Indoles; Male; Mevalonic Acid; Mice; Mice, Nude; Models, Biological; Multiple Myeloma; p38 Mitogen-Activated Protein Kinases; Panobinostat; Prostatic Neoplasms; Reactive Oxygen Species; Signal Transduction; Xenograft Model Antitumor Assays; Zoledronic Acid

2013
Hyperammonemic encephalopathy in multiple myeloma.
    Annals of hematology, 2014, Volume: 93, Issue:8

    Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Boronic Acids; Bortezomib; Brain; Brain Edema; Coma; Cyclophosphamide; Dexamethasone; Diphosphonates; Fatal Outcome; Humans; Hyperammonemia; Imidazoles; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteolysis; Pyrazines; Tomography, X-Ray Computed; Zoledronic Acid

2014
Nuclear factor-kappa B ligand and osteoprotegerin levels in serum and gingival crevicular fluid in patients with bone metastases treated with zoledronic acid.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Follow-Up Studies; Gingival Crevicular Fluid; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplasms; Osteoprotegerin; Prognosis; RANK Ligand; Survival Rate; Zoledronic Acid

2014
[Effect of the administration of zoledronic acid on life expectancy in patients with multiple myeloma with or without renal impairment].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Life Expectancy; Male; Middle Aged; Multiple Myeloma; Renal Insufficiency; Retrospective Studies; Treatment Outcome; Zoledronic Acid

2014
Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:3

    Topics: Aged; Bone Density Conservation Agents; Bone Resorption; Cohort Studies; Comparative Effectiveness Research; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pamidronate; Propensity Score; Proportional Hazards Models; Registries; Survival Rate; Veterans; Zoledronic Acid

2015
Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Jul-10, Volume: 32, Issue:20

    Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Biopsy; Bone Density Conservation Agents; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulin G; Immunoglobulin lambda-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Referral and Consultation; Thalidomide; Translocation, Genetic; Transplantation, Autologous; Zoledronic Acid

2014
Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Aug-01, Volume: 20, Issue:15

    Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Collagen Type I; Cytokines; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Osteonecrosis; Pamidronate; Peptides; Prognosis; Zoledronic Acid

2014
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
    Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:4

    Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Germany; Hematologic Neoplasms; Humans; Ibandronic Acid; Imidazoles; Jaw Diseases; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Registries; Risk Factors; Sex Factors; Time Factors; Zoledronic Acid

2015
Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: a case report.
    Journal of medical case reports, 2014, Oct-23, Volume: 8

    Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Multiple Myeloma; Tomography, X-Ray Computed; Vitamin D Deficiency; Zoledronic Acid

2014
Markers of bone metabolism in multiple myeloma patients switched from zoledronic acid to denosumab.
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:11

    Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Calcium; Cell Differentiation; Collagen Type I; Denosumab; Diphosphonates; Drug Substitution; Female; Humans; Imidazoles; Isoenzymes; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Osteoblasts; Osteocalcin; Osteogenesis; Peptides; RANK Ligand; Retrospective Studies; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid

2014
NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Animals; Bone and Bones; Bone Diseases; Bone Marrow; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Multiple Myeloma; Neoplasm Transplantation; Oligopeptides; Tumor Cells, Cultured; Zoledronic Acid

2015
Isopentenyl pyrophosphate secreted from Zoledronate-stimulated myeloma cells, activates the chemotaxis of γδT cells.
    Biochemical and biophysical research communications, 2015, Aug-07, Volume: 463, Issue:4

    Topics: Cell Line, Tumor; Chemotaxis, Leukocyte; Culture Media, Conditioned; Diphosphonates; Hemiterpenes; Humans; Imidazoles; Multiple Myeloma; Organophosphorus Compounds; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid

2015
[Management of bone disease in myeloma patients: zoledronic acid or denosumab?].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2015, Volume: 56, Issue:8

    Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Denosumab; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Zoledronic Acid

2015
Not all ST-segment changes are myocardial injury: hypercalcaemia-induced ST-segment elevation.
    BMJ case reports, 2015, Oct-13, Volume: 2015

    Topics: Aged, 80 and over; Bone Density Conservation Agents; Brugada Syndrome; Cardiac Conduction System Disease; Diagnosis, Differential; Diphosphonates; Diuretics; Echocardiography; Electrocardiography; Follow-Up Studies; Furosemide; Humans; Hypercalcemia; Imidazoles; Male; Multiple Myeloma; Myocardial Ischemia; Point-of-Care Testing; Treatment Outcome; Zoledronic Acid

2015
[Clinical significance of serum bone metabolic markers in diagnosis and monitoring of myeloma bone disease].
    Zhonghua yi xue za zhi, 2015, Nov-10, Volume: 95, Issue:42

    Topics: Acid Phosphatase; Biomarkers; Collagen Type I; Diphosphonates; Humans; Imidazoles; Isoenzymes; Multiple Myeloma; Osteoporosis; Procollagen; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid

2015
Two diagnoses from bone marrow biopsy: multiple myeloma and Paget's disease of bone.
    BMJ case reports, 2016, Feb-24, Volume: 2016

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Bortezomib; Dexamethasone; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Osteitis Deformans; Treatment Outcome; Zoledronic Acid

2016
Severe clavicular disease in multiple myeloma.
    British journal of haematology, 2016, Volume: 173, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clavicle; Diphosphonates; Female; Humans; Imidazoles; Magnetic Resonance Imaging; Multiple Myeloma; Shoulder Fractures; Stem Cell Transplantation; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vertebroplasty; Zoledronic Acid

2016
Autofluorescence as indicator for detecting the surgical margins of medication-related osteonecrosis of the jaws.
    Minerva stomatologica, 2016, Volume: 65, Issue:4

    Topics: Aged; Aged, 80 and over; Bicuspid; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Breast Neoplasms; Cementoplasty; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Laser Therapy; Lasers, Solid-State; Lung Neoplasms; Male; Margins of Excision; Middle Aged; Multiple Myeloma; Optical Imaging; Postoperative Complications; Tooth Extraction; Zoledronic Acid

2016
Expansion of Th
    Leukemia, 2017, Volume: 31, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Diphosphonates; Humans; Imidazoles; Immunologic Factors; Lenalidomide; Multiple Myeloma; T-Lymphocytes; Th1 Cells; Thalidomide; Zoledronic Acid

2017
CYR61/CCN1 stimulates proliferation and differentiation of osteoblasts in vitro and contributes to bone remodeling in vivo in myeloma bone disease.
    International journal of oncology, 2017, Volume: 50, Issue:2

    Topics: Adult; Aged; Animals; Bone Diseases; Bone Marrow Cells; Bone Remodeling; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cysteine-Rich Protein 61; Diphosphonates; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; Mice; Middle Aged; Multiple Myeloma; Neoplasm Transplantation; Osteoblasts; Wnt Signaling Pathway; Zoledronic Acid

2017
Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients.
    Clinical lymphoma, myeloma & leukemia, 2017, Volume: 17, Issue:4

    Topics: Adult; Aged; Bone Density Conservation Agents; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Quality of Life; Zoledronic Acid

2017
Consequence of therapy discontinuation in bisphosphonate-associated osteonecrosis of the jaws.
    The British journal of oral & maxillofacial surgery, 2009, Volume: 47, Issue:1

    Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents, Local; Bone Density Conservation Agents; Bone Neoplasms; Chlorhexidine; Debridement; Diphosphonates; Female; Humans; Hydrogen Peroxide; Imidazoles; Maxillary Diseases; Middle Aged; Mouthwashes; Multiple Myeloma; Oroantral Fistula; Osteonecrosis; Tooth Extraction; Zoledronic Acid

2009
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dental Prophylaxis; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pyrazines; Retrospective Studies; Thalidomide; Young Adult; Zoledronic Acid

2009
Radiology quiz case. Osteonecrosis of the jaw: aminobisphosphonate epidemic.
    Archives of otolaryngology--head & neck surgery, 2008, Volume: 134, Issue:11

    Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Disease Outbreaks; Humans; Image Processing, Computer-Assisted; Imidazoles; Male; Mandibular Diseases; Multiple Myeloma; Osteonecrosis; Radiography, Panoramic; Reoperation; Tomography, Spiral Computed; Zoledronic Acid

2008
[Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma].
    Ugeskrift for laeger, 2009, Jan-05, Volume: 171, Issue:1-2

    Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw; Multiple Myeloma; Oral Hygiene; Osteonecrosis; Pamidronate; Risk Factors; Zoledronic Acid

2009
Effects of platelet-derived growth factor, vitamin D and parathyroid hormone on osteoblasts derived from cancer patients on chronic bisphosphonate therapy.
    International journal of molecular medicine, 2009, Volume: 23, Issue:3

    Topics: Aged; Antigens, Differentiation; Bone Density Conservation Agents; Bone Regeneration; Breast Neoplasms; Calcitriol; Cell Differentiation; Cells, Cultured; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Osteoblasts; Parathyroid Hormone; Platelet-Derived Growth Factor; Vitamin D; Zoledronic Acid

2009
Recurrent low-energy femoral shaft fractures and osteonecrosis of the jaw in a case of multiple myeloma treated with bisphosphonates.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2009, Volume: 67, Issue:3

    Topics: Bone Density Conservation Agents; Cross Infection; Diphosphonates; Escherichia coli Infections; Fatal Outcome; Femoral Fractures; Fractures, Spontaneous; Humans; Imidazoles; Injections, Intravenous; Male; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Osteopetrosis; Recurrence; Zoledronic Acid

2009
Bisphosphonate-related osteonecrosis of the skull base.
    The Laryngoscope, 2009, Volume: 119, Issue:3

    Topics: Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Neurosurgical Procedures; Osteonecrosis; Skull Base; Tomography, X-Ray Computed; Zoledronic Acid

2009
Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
    Journal of bone and mineral metabolism, 2009, Volume: 27, Issue:4

    Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Jaw; Male; Middle Aged; Multiple Myeloma; Necrosis; Osteoclasts; Osteonecrosis; Thalidomide; Zoledronic Acid

2009
The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
    International journal of cancer, 2010, Jan-01, Volume: 126, Issue:1

    Topics: Animals; Apoptosis; Bone Density Conservation Agents; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Mice; Mice, SCID; Multiple Myeloma; Protein Prenylation; Transplantation, Heterologous; Zoledronic Acid

2010
[Case of acute kidney injury related to intravenous zoledronic acid in a patient with multiple myeloma].
    Nihon Jinzo Gakkai shi, 2009, Volume: 51, Issue:5

    Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases; Dexamethasone; Diphosphonates; Doxorubicin; Humans; Imidazoles; Injections, Intravenous; Male; Multiple Myeloma; Renal Dialysis; Treatment Outcome; Vincristine; Zoledronic Acid

2009
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-10, Volume: 27, Issue:32

    Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Greece; Humans; Ibandronic Acid; Imidazoles; Incidence; Jaw Diseases; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Risk Factors; Zoledronic Acid

2009
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
    Cancer investigation, 2009, Volume: 27, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Jaw Diseases; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Retrospective Studies; Spinal Cord Compression; Time Factors; Treatment Outcome; Zoledronic Acid

2009
Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:2

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Adhesion; Cell Movement; Cell Proliferation; Diphosphonates; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Macrophages; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; NF-kappa B; Phosphorylation; Pyrazines; Vascular Endothelial Growth Factor Receptor-2; Zoledronic Acid

2010
IgE-type multiple myeloma with the late development of IgA2 kappa and plasma cell leukaemia.
    Pathology, 2010, Volume: 42, Issue:1

    Topics: Aged; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Diphosphonates; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Imidazoles; Immunoglobulin A; Immunoglobulin E; Immunoglobulin kappa-Chains; Leukemia, Plasma Cell; Melphalan; Multiple Myeloma; Myeloma Proteins; Neoplasms, Second Primary; Prednisone; Zoledronic Acid

2010
Bisphosphonate-induced osteonecrosis of the jaw 32 months after interruption of zoledronate in a patient with multiple myeloma.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2010, Volume: 68, Issue:5

    Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Maxillary Diseases; Multiple Myeloma; Oroantral Fistula; Osteonecrosis; Zoledronic Acid

2010
Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease.
    Leukemia, 2010, Volume: 24, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Diseases; Clinical Trials, Phase III as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Osteolysis; Pamidronate; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid

2010
Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Treatment Outcome; Zoledronic Acid

2010
Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma.
    British journal of haematology, 2010, Volume: 151, Issue:1

    Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Zoledronic Acid

2010
Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells.
    Leukemia research, 2011, Volume: 35, Issue:4

    Topics: Apoptosis; Biosynthetic Pathways; Cell Line, Tumor; Diphosphonates; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Immunoblotting; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Lovastatin; Multiple Myeloma; Prenylation; rab1 GTP-Binding Proteins; Reverse Transcriptase Polymerase Chain Reaction; Terpenes; Tunicamycin; Unfolded Protein Response; Zoledronic Acid

2011
Mechanisms behind the anti-tumour effects of zoledronic acid use in multiple myeloma.
    British journal of haematology, 2010, Volume: 151, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Zoledronic Acid

2010
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.
    Experimental hematology, 2011, Volume: 39, Issue:1

    Topics: Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Oxides; Polymerase Chain Reaction; Pyrazines; Zoledronic Acid

2011
Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.
    American journal of hematology, 2011, Volume: 86, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Prognosis; Retrospective Studies; Risk Factors; Zoledronic Acid

2011
Zoledronic acid in myeloma: MRC Myeloma IX.
    Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757

    Topics: Administration, Oral; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Drug Administration Schedule; Humans; Imidazoles; Infusions, Intravenous; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zoledronic Acid

2010
Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw.
    Frontiers in bioscience (Elite edition), 2011, 01-01, Volume: 3, Issue:1

    Topics: Bone Density Conservation Agents; Diphosphonates; Female; Gene Frequency; Genetic Predisposition to Disease; Geranyltranstransferase; Humans; Imidazoles; Italy; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Pharmacogenetics; Polymorphism, Single Nucleotide; Retrospective Studies; White People; Zoledronic Acid

2011
Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2011, Volume: 40, Issue:6

    Topics: Bone Density Conservation Agents; Breast Neoplasms; Case-Control Studies; Chi-Square Distribution; Diphosphonates; Female; Haplotypes; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Odds Ratio; Osteonecrosis; Polymorphism, Single Nucleotide; Vascular Endothelial Growth Factor A; Zoledronic Acid

2011
Development of multiple myeloma in a case of longstanding ankylosing spondylitis: more than a coincidence?
    International journal of rheumatic diseases, 2011, Volume: 14, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diphosphonates; Etoricoxib; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pyridines; Sacroiliitis; Spondylitis, Ankylosing; Sulfones; Thalidomide; Zoledronic Acid

2011
Zoledronic acid: a framework of emerging anticancer evidence throughout the cancer continuum.
    Critical reviews in oncology/hematology, 2011, Volume: 77 Suppl 1

    Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Zoledronic Acid

2011
[Case report; a case of acute kidney injury due to intravenous zoledronic acid hydrate, improved with bortezomib plus dexamethazone therapy in a patient with multiple myeloma].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2011, Jan-10, Volume: 100, Issue:1

    Topics: Acute Kidney Injury; Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Injections, Intravenous; Male; Multiple Myeloma; Pyrazines; Zoledronic Acid

2011
Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw.
    International journal of oral and maxillofacial surgery, 2011, Volume: 40, Issue:6

    Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Bone Density Conservation Agents; Cohort Studies; Collagen Type I; Collagen Type I, alpha 1 Chain; Cytochrome P-450 CYP2C8; Diphosphonates; Female; Gene Frequency; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Matrix Metalloproteinase 2; Middle Aged; Multiple Myeloma; Osteonecrosis; Osteopontin; Osteoprotegerin; Pamidronate; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Receptor Activator of Nuclear Factor-kappa B; Risk Factors; Smoking; Time Factors; Tumor Necrosis Factor-alpha; Zoledronic Acid

2011
Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes.
    Nanomedicine : nanotechnology, biology, and medicine, 2011, Volume: 7, Issue:6

    Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Delivery Systems; Humans; Imidazoles; Liposomes; Male; Mice; Mice, Nude; Multiple Myeloma; Neovascularization, Pathologic; Prostate; Prostatic Neoplasms; Zoledronic Acid

2011
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling.
    British journal of haematology, 2011, Volume: 154, Issue:4

    Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Gene Frequency; Genetic Predisposition to Disease; Humans; Imidazoles; Jaw Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Polymorphism, Single Nucleotide; PPAR gamma; Zoledronic Acid

2011
Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-01, Volume: 29, Issue:19

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biopsy; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Protein Processing, Post-Translational; Randomized Controlled Trials as Topic; RANK Ligand; ras Proteins; Treatment Outcome; Zoledronic Acid

2011
Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells.
    International journal of hematology, 2011, Volume: 94, Issue:1

    Topics: Cell Communication; Cell Culture Techniques; Cell Movement; Cytotoxicity, Immunologic; Diphosphonates; Humans; Imidazoles; Interleukin-2; Multiple Myeloma; Osteoclasts; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid

2011
Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.
    Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:4

    Topics: Aged; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Comorbidity; Diphosphonates; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid

2011
Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vγ9Vδ2 T cells, αβ CD8+ T cells, regulatory T cells, and dendritic cells.
    Journal of immunology (Baltimore, Md. : 1950), 2011, Aug-15, Volume: 187, Issue:4

    Topics: B7-1 Antigen; Bone Density Conservation Agents; CD8-Positive T-Lymphocytes; Cell Communication; Cell Proliferation; Dendritic Cells; Diphosphonates; Gene Expression Regulation; Hemiterpenes; Humans; Imidazoles; Lymphocyte Activation; Mevalonic Acid; Monocytes; Multiple Myeloma; Organophosphorus Compounds; Programmed Cell Death 1 Ligand 2 Protein; Receptors, Antigen, T-Cell, alpha-beta; Receptors, Antigen, T-Cell, gamma-delta; Zoledronic Acid

2011
Zoledronic acid for all patients with newly diagnosed multiple myeloma?
    The Lancet. Oncology, 2011, Volume: 12, Issue:8

    Topics: Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Male; Multiple Myeloma; Zoledronic Acid

2011
Further analyses of the Myeloma IX Study.
    Lancet (London, England), 2011, Aug-27, Volume: 378, Issue:9793

    Topics: Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Osteonecrosis; Thrombosis; Zoledronic Acid

2011
Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study.
    Oral oncology, 2012, Volume: 48, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lasers, Semiconductor; Low-Level Light Therapy; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Platelet-Rich Plasma; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Treatment Outcome; Zoledronic Acid

2012
Bisphosphonate-associated osteonecrosis of the jaw: a six-year history of a case.
    The New Zealand dental journal, 2011, Volume: 107, Issue:3

    Topics: Bone Density Conservation Agents; Debridement; Diphosphonates; Disease Progression; Follow-Up Studies; Humans; Imidazoles; Immunoglobulin kappa-Chains; Male; Mandibular Diseases; Mandibular Neoplasms; Middle Aged; Multiple Myeloma; Osteonecrosis; Recurrence; Zoledronic Acid

2011
The Medical Research Council Myeloma IX Trial: new clinical insights on the anticancer effects of zoledronic acid in patients with multiple myeloma.
    Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid

2012
Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective.
    Journal of medical economics, 2012, Volume: 15, Issue:3

    Topics: Bone Density Conservation Agents; Clodronic Acid; Cost-Benefit Analysis; Delivery of Health Care; Diphosphonates; Humans; Imidazoles; Models, Economic; Multiple Myeloma; Quality-Adjusted Life Years; Survival Analysis; United Kingdom; Zoledronic Acid

2012
Bisphosphonate therapy in multiple myeloma in preventing vertebral collapses: preliminary report.
    European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2012, Volume: 21 Suppl 1

    Topics: Adult; Aged; Bone Diseases; Bone Resorption; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteogenesis; Pain Measurement; Positron-Emission Tomography; Quality of Life; Retrospective Studies; Spine; Treatment Outcome; Zoledronic Acid

2012
Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma.
    American journal of hematology, 2012, Volume: 87, Issue:5

    Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Databases, Factual; Diphosphonates; Drug Utilization; Female; Fractures, Spontaneous; Humans; Imidazoles; Incidence; Infusions, Intravenous; International Classification of Diseases; Male; Medication Adherence; Middle Aged; Multiple Myeloma; Osteolysis; Retrospective Studies; Treatment Outcome; United States; Zoledronic Acid

2012
Myeloma: diagnosis complications and supportive care.
    Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1

    Topics: Amyloidosis; Anemia; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Pyrazines; Quality of Life; Renal Insufficiency; Thrombosis; Zoledronic Acid

2012
Radical surgical treatment of bisphosphonate related osteonecrosis of the jaw.
    Australian dental journal, 2012, Volume: 57, Issue:2

    Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Maxillary Diseases; Maxillary Osteotomy; Middle Aged; Multiple Myeloma; Pamidronate; Peptides; Surgical Flaps; Tooth Extraction; Zoledronic Acid

2012
Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid.
    Clinical oral investigations, 2013, Volume: 17, Issue:4

    Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Case-Control Studies; Cell Proliferation; Cytokines; Diphosphonates; Endothelial Cells; Female; Gingival Crevicular Fluid; Humans; Hydroxymethylglutaryl CoA Reductases; Imidazoles; Injections, Intravenous; Interleukin-6; Male; Middle Aged; Mouth Mucosa; Multiple Myeloma; Osteoclasts; Osteoprotegerin; RANK Ligand; Statistics, Nonparametric; Vascular Endothelial Growth Factor A; Zoledronic Acid

2013
Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Animals; Bone and Bones; CD11b Antigen; Cell Differentiation; Cell Line, Tumor; Diphosphonates; Female; Humans; Imidazoles; Mice; Multiple Myeloma; Myeloid Cells; Osteoclasts; Prenylation; Tumor Microenvironment; Zoledronic Acid

2012
Updates in the treatment of multiple myeloma.
    Clinical advances in hematology & oncology : H&O, 2012, Volume: 10, Issue:10

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; B-Cell Maturation Antigen; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Disease Management; Humans; Imidazoles; Killer Cells, Natural; Multiple Myeloma; Proteasome Inhibitors; Quality of Life; Recurrence; Survival Analysis; T-Lymphocytes; Zoledronic Acid

2012
Bisphosphonate-related osteonecrosis of the jaws--a case report.
    Compendium of continuing education in dentistry (Jamesburg, N.J. : 1995), 2012, Volume: 33, Issue:5

    Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Comorbidity; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Zoledronic Acid

2012
Risk factors for renal impairment in patients with solid tumors or multiple myeloma treated with zoledronic acid.
    International journal of clinical pharmacology and therapeutics, 2013, Volume: 51, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Contraindications; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hospitals, Teaching; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasms; Practice Guidelines as Topic; Renal Insufficiency; Republic of Korea; Retrospective Studies; Risk Factors; Zoledronic Acid

2013
Bortezomib induced a phrenic palsy in a multiple myeloma patient.
    Annals of hematology, 2013, Volume: 92, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diagnosis, Differential; Diphosphonates; gamma-Aminobutyric Acid; Humans; Imidazoles; Male; Melphalan; Multiple Myeloma; Nerve Compression Syndromes; Neuralgia; Phrenic Nerve; Prednisone; Pregabalin; Protease Inhibitors; Pyrazines; Respiratory Paralysis; Zoledronic Acid

2013
FDA approves ZOMETA for treatment of cancer-related bone complications.
    Expert review of anticancer therapy, 2002, Volume: 2, Issue:2

    Topics: Bone Neoplasms; Diphosphonates; Drug Approval; Humans; Imidazoles; Infusions, Intravenous; Multiple Myeloma; United States; United States Food and Drug Administration; Zoledronic Acid

2002
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Sep-01, Volume: 20, Issue:17

    Topics: Clodronic Acid; Diphosphonates; Drug Monitoring; Humans; Imidazoles; Multiple Myeloma; Osteolysis; Pamidronate; Zoledronic Acid

2002
The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells.
    International journal of oncology, 2002, Volume: 21, Issue:4

    Topics: Antineoplastic Agents, Hormonal; Apoptosis; Cell Division; Dexamethasone; Diphosphonates; Drug Synergism; Flow Cytometry; Humans; Imidazoles; Interleukin-6; Membrane Glycoproteins; Multiple Myeloma; Proteoglycans; Receptors, Interleukin-6; Syndecans; Time Factors; Tumor Cells, Cultured; Zoledronic Acid

2002
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
    The oncologist, 2002, Volume: 7, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Neoplasms; Cystitis; Diphosphonates; Drug Approval; Gastrointestinal Neoplasms; Hematuria; Hemorrhage; Humans; Ifosfamide; Imatinib Mesylate; Imidazoles; Mesna; Multiple Myeloma; Orphan Drug Production; Piperazines; Protective Agents; Pyrimidines; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Zoledronic Acid

2002
Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma.
    British journal of haematology, 2002, Volume: 119, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pamidronate; Plasma Cells; Protein Prenylation; Tumor Cells, Cultured; Zoledronic Acid

2002
Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions.
    British journal of haematology, 2002, Volume: 119, Issue:2

    Topics: Aged; Creatinine; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Immunosuppressive Agents; Male; Multiple Myeloma; Thalidomide; Zoledronic Acid

2002
Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2003, Volume: 18, Issue:3

    Topics: Animals; Bone Density; Diphosphonates; Disease-Free Survival; Imidazoles; Mice; Mice, Inbred C57BL; Multiple Myeloma; Neovascularization, Pathologic; Zoledronic Acid

2003
How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics.
    British journal of haematology, 2003, Volume: 122, Issue:2

    Topics: Alendronate; Alkyl and Aryl Transferases; Apoptosis; Blotting, Western; Diphosphonates; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Geranyltranstransferase; Humans; Imidazoles; Linear Models; Multiple Myeloma; Polymerase Chain Reaction; Treatment Failure; Tumor Cells, Cultured; Zoledronic Acid

2003
Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo.
    Blood, 2003, Sep-15, Volume: 102, Issue:6

    Topics: Diphosphonates; Humans; Imidazoles; Lymphoma, Non-Hodgkin; Multiple Myeloma; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid

2003
The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide.
    International journal of hematology, 2003, Volume: 78, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Calcium; Cell Cycle; Cell Division; Dexamethasone; Diphosphonates; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Egtazic Acid; Enzyme Inhibitors; Humans; Imidazoles; Leukemia, Plasma Cell; Multiple Myeloma; Neoplasm Proteins; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Protein Kinase C; Staurosporine; Thalidomide; Tumor Cells, Cultured; Zoledronic Acid

2003
Treatment strategies for myeloma bone disease.
    Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:12

    Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Orthopedic Procedures; Pamidronate; Zoledronic Acid

2003
Symptomatic hypocalcaemia after treatment with zoledronic acid in a patient with multiple myeloma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:12

    Topics: Calcium; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Middle Aged; Multiple Myeloma; Zoledronic Acid

2004
Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines.
    International journal of radiation oncology, biology, physics, 2005, Feb-01, Volume: 61, Issue:2

    Topics: Animals; Cell Line, Tumor; Combined Modality Therapy; Diphosphonates; Drug Screening Assays, Antitumor; Humans; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; Radiation Tolerance; Radiotherapy Dosage; Zoledronic Acid

2005
Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma.
    American journal of clinical oncology, 2005, Volume: 28, Issue:1

    Topics: Ambulatory Care; Bone Neoplasms; Breast Neoplasms; Costs and Cost Analysis; Diphosphonates; Female; Hospitalization; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid

2005
Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.
    Leukemia, 2005, Volume: 19, Issue:4

    Topics: Antineoplastic Agents; Cell Communication; Cell Division; Cells, Cultured; Diphosphonates; Humans; Imidazoles; Immunologic Factors; Immunologic Memory; In Vitro Techniques; Interleukin-2; Multiple Myeloma; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Zoledronic Acid

2005
Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma.
    British journal of haematology, 2005, Volume: 128, Issue:6

    Topics: Aged; Diphosphonates; Humans; Imidazoles; Jaw; Male; Multiple Myeloma; Osteonecrosis; Zoledronic Acid

2005
[Rapid drug information].
    Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2005, Volume: 48, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Information Services; Germany; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Osteoporosis; Pamidronate; Risk Assessment; Zoledronic Acid

2005
Profound hypocalcaemia after zoledronic acid treatment.
    The Medical journal of Australia, 2005, May-02, Volume: 182, Issue:9

    Topics: Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Multiple Myeloma; Zoledronic Acid

2005
Osteonecrosis of the jaw and bisphosphonates.
    The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1

    Topics: Breast Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Pamidronate; Risk Factors; Zoledronic Acid

2005
Osteonecrosis of the jaw and bisphosphonates.
    The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1

    Topics: Breast Neoplasms; Dental Care; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Risk Factors; Zoledronic Acid

2005
Evolving therapeutic role of bisphosphonates in multiple myeloma.
    British journal of cancer, 2005, Jul-25, Volume: 93, Issue:2

    Topics: Apoptosis; Cell Proliferation; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Zoledronic Acid

2005
Zoledronic acid sensitizes tumor cells to radiation: in response to Algur et al. (Int J Radiat Oncol Biol Phys 2005;61:535-542).
    International journal of radiation oncology, biology, physics, 2005, Nov-01, Volume: 63, Issue:3

    Topics: Animals; Cell Cycle; Cell Line, Tumor; Combined Modality Therapy; Diphosphonates; Humans; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; Proto-Oncogene Proteins p21(ras); Radiation Tolerance; Radiation-Sensitizing Agents; Zoledronic Acid

2005
Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2005, Volume: 34, Issue:10

    Topics: Aged; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Curettage; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Mandibular Diseases; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Recurrence; Zoledronic Acid

2005
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2005, Volume: 63, Issue:11

    Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Dental Caries; Dexamethasone; Diphosphonates; Drug Interactions; Female; Humans; Hyperostosis; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Osteopetrosis; Osteoporosis; Pamidronate; Periodontitis; Prostatic Neoplasms; Risk Factors; Tooth Extraction; Zoledronic Acid

2005
Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?
    Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2005, Volume: 33, Issue:6

    Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Mandibular Diseases; Maxillary Diseases; Multiple Myeloma; Osteomyelitis; Osteonecrosis; Zoledronic Acid

2005
Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.
    Internal medicine journal, 2005, Volume: 35, Issue:12

    Topics: Acute Kidney Injury; Aged; Bone Density Conservation Agents; Calcitriol; Calcium Carbonate; Diphosphonates; Fatal Outcome; Female; Humans; Hypocalcemia; Imidazoles; Injections, Intravenous; Magnesium Deficiency; Male; Middle Aged; Multiple Myeloma; Pamidronate; Zoledronic Acid

2005
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Greece; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prospective Studies; Prostatic Neoplasms; Risk Factors; Time Factors; Treatment Failure; Zoledronic Acid

2005
Consumer groups look to improve adverse event reporting systems.
    Journal of the National Cancer Institute, 2005, Dec-21, Volume: 97, Issue:24

    Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Bone Density Conservation Agents; Consumer Behavior; Diphosphonates; Drug Approval; Humans; Imidazoles; Multiple Myeloma; Osteonecrosis; Pamidronate; Product Surveillance, Postmarketing; United States; United States Food and Drug Administration; Zoledronic Acid

2005
Osteonecrosis of the jaws and bisphosphonates. Report of three cases.
    Medicina oral, patologia oral y cirugia bucal, 2006, Jan-01, Volume: 11, Issue:1

    Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Tooth Extraction; Zoledronic Acid

2006
Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications.
    The New Zealand dental journal, 2006, Volume: 102, Issue:1

    Topics: Adenocarcinoma; Aged, 80 and over; Bone Density Conservation Agents; Carcinoma; Diabetes Mellitus, Type 2; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Patient Care Planning; Tooth Extraction; Zoledronic Acid

2006
Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases.
    International journal of oral and maxillofacial surgery, 2006, Volume: 35, Issue:7

    Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Retrospective Studies; Tooth Extraction; Zoledronic Acid

2006
Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: possible mechanisms?
    Acta oncologica (Stockholm, Sweden), 2006, Volume: 45, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Diphosphonates; Docetaxel; Drug Synergism; Humans; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; Taxoids; Zoledronic Acid

2006
[Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis].
    Ugeskrift for laeger, 2006, May-22, Volume: 168, Issue:21

    Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Pamidronate; Zoledronic Acid

2006
Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws.
    Dento maxillo facial radiology, 2006, Volume: 35, Issue:4

    Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Radiography, Panoramic; Radionuclide Imaging; Retrospective Studies; Technetium Tc 99m Medronate; Tomography, X-Ray Computed; Zoledronic Acid

2006
Synergistic antimyeloma effects of zoledronate and simvastatin.
    Anti-cancer drugs, 2006, Volume: 17, Issue:6

    Topics: Apoptosis; Bone Density Conservation Agents; Bone Marrow; Cell Adhesion; Cell Line, Tumor; Diphosphonates; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Multiple Myeloma; Simvastatin; Stromal Cells; Zoledronic Acid

2006
Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
    Wiener klinische Wochenschrift, 2006, Volume: 118, Issue:15-16

    Topics: Adult; Aged; Biopsy; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Histiocytosis, Langerhans-Cell; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Magnetic Resonance Imaging; Male; Mandible; Mandibular Diseases; Maxilla; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Radiography, Panoramic; Radionuclide Imaging; Retrospective Studies; Risk Factors; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid

2006
Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.
    Leukemia research, 2007, Volume: 31, Issue:3

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphosphonates; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Imidazoles; Indoles; Mevalonic Acid; Multiple Myeloma; Piperidines; Pyridines; Structure-Activity Relationship; Zoledronic Acid

2007
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
    The Lancet. Oncology, 2006, Volume: 7, Issue:11

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Clarithromycin; Dexamethasone; Diphosphonates; Glomerulonephritis; Humans; Idarubicin; Imidazoles; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Pamidronate; Protein Synthesis Inhibitors; Pyrazines; Skin Neoplasms; Thalidomide; Zoledronic Acid

2006
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
    British journal of haematology, 2006, Volume: 135, Issue:5

    Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Remodeling; Boronic Acids; Bortezomib; Case-Control Studies; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; Isoenzymes; Male; Middle Aged; Multiple Myeloma; Osteocalcin; Osteoprotegerin; Peptides; Protease Inhibitors; Pyrazines; RANK Ligand; Recurrence; Statistics, Nonparametric; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid

2006
The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma.
    Haematologica, 2006, Volume: 91, Issue:12

    Topics: Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Osteoprotegerin; Zoledronic Acid

2006
Jaw osteonecrosis associated with bisphosphonates.
    The New Zealand medical journal, 2006, Dec-01, Volume: 119, Issue:1246

    Topics: Aged; Diphosphonates; Fatal Outcome; Humans; Imidazoles; Male; Maxilla; Multiple Myeloma; Osteonecrosis; Radiography; Zoledronic Acid

2006
[Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid].
    Medicina clinica, 2006, Oct-21, Volume: 127, Issue:15

    Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Risk Factors; Zoledronic Acid

2006
Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2006, Volume: 12, Issue:4

    Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Creatinine; Diphosphonates; Drug Administration Schedule; Drug Costs; Female; Health Care Costs; Humans; Imidazoles; Infusions, Intravenous; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Pamidronate; Prevalence; Registries; Retrospective Studies; Treatment Outcome; Zoledronic Acid

2006
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
    Acta haematologica, 2007, Volume: 117, Issue:3

    Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Mandible; Maxilla; Middle Aged; Multiple Myeloma; Necrosis; Osteonecrosis; Pamidronate; Tomography, X-Ray Computed; Zoledronic Acid

2007
[Osteonecrosis associated with the use of biphosphonates: Case report].
    Revista medica de Chile, 2006, Volume: 134, Issue:9

    Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Pamidronate; Zoledronic Acid

2006
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
    Acta bio-medica : Atenei Parmensis, 2006, Volume: 77, Issue:2

    Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conservation Agents; Bone Neoplasms; Chlorhexidine; Curettage; Diphosphonates; Female; Humans; Hydrogen Peroxide; Imidazoles; Jaw Diseases; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Mouthwashes; Multiple Myeloma; Osteonecrosis; Osteoporosis; Pamidronate; Radiography; Time Factors; Zoledronic Acid

2006
Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2007, Volume: 103, Issue:3

    Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Zoledronic Acid

2007
Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: Report of 3 cases.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2007, Volume: 65, Issue:2

    Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Mandibular Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Platelet-Rich Plasma; Tooth Extraction; Zoledronic Acid

2007
Morphoproteomic expression of H-ras (p21ras) correlates with serum monoclonal immunoglobulin reduction in multiple myeloma patients following pamidronate treatment.
    Annals of clinical and laboratory science, 2007,Winter, Volume: 37, Issue:1

    Topics: Alkyl and Aryl Transferases; Biomarkers; Cell Proliferation; Diphosphonates; Farnesyltranstransferase; Humans; Imidazoles; Immunoglobulin A; Immunoglobulin G; Immunohistochemistry; Multiple Myeloma; Pamidronate; Pennsylvania; Proto-Oncogene Proteins p21(ras); Zoledronic Acid

2007
Bisphosphonates and jaw osteonecrosis: the UAMS experience.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 136, Issue:3

    Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Bone Density Conservation Agents; Curettage; Dental Care; Diphosphonates; Female; Humans; Hyperbaric Oxygenation; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Retrospective Studies; Time Factors; Treatment Outcome; Zoledronic Acid

2007
[Osteonecrosis of the jawbone as a side effect of intravenous treatment with bisphosphonates].
    Nederlands tijdschrift voor geneeskunde, 2007, Feb-03, Volume: 151, Issue:5

    Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Male; Mandibular Diseases; Multiple Myeloma; Oral Hygiene; Osteonecrosis; Zoledronic Acid

2007
A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma.
    Leukemia, 2007, Volume: 21, Issue:7

    Topics: Aged; Diphosphonates; Drug Administration Schedule; Drug Evaluation; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Retrospective Studies; Risk Factors; Zoledronic Acid

2007
Potential effect of zoledronate therapy in heavy proteinuria.
    Clinical nephrology, 2007, Volume: 67, Issue:4

    Topics: Biopsy; Bone Density Conservation Agents; Diphosphonates; Female; Glucocorticoids; Humans; Hypercalcemia; Imidazoles; Middle Aged; Multiple Myeloma; Prednisone; Proteinuria; Zoledronic Acid

2007
Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:8

    Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Glomerulosclerosis, Focal Segmental; Humans; Imidazoles; Kidney; Male; Multiple Myeloma; Nephrotic Syndrome; Time Factors; Treatment Outcome; Zoledronic Acid

2007
Therapeutic role of bisphosphonate and radiation combination in the management of myeloma bone disease.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jun-01, Volume: 13, Issue:11

    Topics: Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Cell Cycle; Combined Modality Therapy; Diphosphonates; Disease Progression; Humans; Imidazoles; Multiple Myeloma; Orthopedics; Radiopharmaceuticals; Zoledronic Acid

2007
Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2007, Volume: 65, Issue:8

    Topics: Aged; Aged, 80 and over; Alveolar Process; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Mandibular Diseases; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Radiography; Severity of Illness Index; Zoledronic Acid

2007
Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:9

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Vasculitis, Leukocytoclastic, Cutaneous; Zoledronic Acid

2007
Spontaneous bilateral subcapital hip fracture due to multiple myeloma: an 18-month follow-up.
    European journal of cancer care, 2007, Volume: 16, Issue:5

    Topics: Adult; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Femoral Neck Fractures; Fracture Fixation, Internal; Fractures, Spontaneous; Humans; Imidazoles; Male; Multiple Myeloma; Radiography; Zoledronic Acid

2007
Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells.
    European journal of haematology, 2007, Volume: 79, Issue:5

    Topics: Actins; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dexamethasone; Diphosphonates; Diterpenes; Drug Resistance, Neoplasm; Humans; Imidazoles; Multiple Myeloma; Protein Prenylation; rap1 GTP-Binding Proteins; rhoA GTP-Binding Protein; Zoledronic Acid

2007
Intravenous bisphosphonate-associated osteonecrosis of the jaw.
    Journal of periodontology, 2007, Volume: 78, Issue:11

    Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Mandibular Fractures; Multiple Myeloma; Osteonecrosis; Radiography; Zoledronic Acid

2007
Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy.
    Joint bone spine, 2008, Volume: 75, Issue:1

    Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw; Male; Middle Aged; Multiple Myeloma; Orthognathic Surgical Procedures; Osteonecrosis; Osteoporosis; Pamidronate; Prospective Studies; Zoledronic Acid

2008
Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib.
    Acta haematologica, 2007, Volume: 118, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Doxorubicin; Female; Humans; Imidazoles; Mandibular Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Protease Inhibitors; Pyrazines; Tooth Extraction; Transplantation, Autologous; Vincristine; Zoledronic Acid

2007
Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate.
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2008, Volume: 61, Issue:1

    Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Mandibular Diseases; Multiple Myeloma; Osteonecrosis; Radiography, Panoramic; Zoledronic Acid

2008
Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:12 Pt 1

    Topics: Adult; Aged; Base Sequence; Blotting, Western; Culture Media, Conditioned; Diphosphonates; DNA Primers; Enzyme-Linked Immunosorbent Assay; Female; Humans; Imidazoles; Lovastatin; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Phenotype; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A; Zoledronic Acid

2007
Bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma.
    Medicina oral, patologia oral y cirugia bucal, 2008, Jan-01, Volume: 13, Issue:1

    Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Male; Mandibular Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Tooth Extraction; Wound Healing; Zoledronic Acid

2008
Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2008, Volume: 105, Issue:3

    Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw; Jaw Diseases; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Tomography, Spiral Computed; Tooth Extraction; Water; Zoledronic Acid

2008
Case records of the Massachusetts General Hospital. Case 9-2008. A 65-year-old woman with a nonhealing ulcer of the jaw.
    The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12

    Topics: Aged; Diagnosis, Differential; Diphosphonates; Female; Gingiva; Gingival Diseases; Humans; Imidazoles; Mandible; Mandibular Diseases; Multiple Myeloma; Osteonecrosis; Precipitating Factors; Radiography; Tooth Extraction; Ulcer; Zoledronic Acid

2008
The effects of zoledronic acid on serum lipids in multiple myeloma patients.
    Calcified tissue international, 2008, Volume: 82, Issue:4

    Topics: Aged; Aged, 80 and over; Atherosclerosis; Bone Density Conservation Agents; Cholesterol, HDL; Collagen; Diphosphonates; Female; Humans; Imidazoles; Lipids; Male; Middle Aged; Multiple Myeloma; Treatment Outcome; Zoledronic Acid

2008
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid.
    Clinical lymphoma & myeloma, 2008, Volume: 8, Issue:2

    Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Male; Mandible; Maxilla; Middle Aged; Multiple Myeloma; Necrosis; Zoledronic Acid

2008
Zoledronate.
    British journal of clinical practice. Supplement, 1996, Volume: 87

    Topics: Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Osteitis Deformans; Osteoporosis; Zoledronic Acid

1996
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
    Leukemia, 1998, Volume: 12, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Calcium; Cell Death; Cell Division; Cell Survival; Chelating Agents; Diphosphonates; Drug Screening Assays, Antitumor; Humans; Imidazoles; Interleukin-6; Multiple Myeloma; Pamidronate; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Zoledronic Acid

1998
Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1999, Volume: 14, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Bone Resorption; Cell Division; Cell Survival; Diphosphonates; Humans; Imidazoles; Interleukin-1; Interleukin-6; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Multiple Myeloma; Pamidronate; Tumor Cells, Cultured; Zoledronic Acid

1999
Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines.
    Leukemia, 2000, Volume: 14, Issue:5

    Topics: Apoptosis; Cell Division; Dexamethasone; Diphosphonates; Drug Synergism; Flow Cytometry; Humans; Imidazoles; Multiple Myeloma; Tumor Cells, Cultured; Zoledronic Acid

2000
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.
    British journal of haematology, 2002, Volume: 116, Issue:2

    Topics: Animals; Bone Marrow Cells; Bone Transplantation; Cell Division; Diphosphonates; Humans; Imidazoles; Mice; Mice, SCID; Multiple Myeloma; Osteoclasts; Pamidronate; Transplantation, Heterologous; Zoledronic Acid

2002